A Phase 3 interventional study of BNT162b2 and Placebo in SARS-CoV-2 Infection and COVID-19, sponsored by BioNTech SE. Completed at 154 sites in 5 countries. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-10.
Sponsored by BioNTech SE · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.
Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 2nd largest by enrollment, is one of 30 that started in 2021, is one of 18 in phase 3, and was the 18th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Technical University of Munich · Sites in Austria, Belgium, Germany and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
PharmaJet, Inc. · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 12 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 23 · Phase 4 11
First in 2020; this study’s year is marked. 30 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16,372 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 575 across the 54 interventional studies. Of the 39 that completed or were terminated, 28 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
35 studies in COVID-19 by BioNTech SE: 2 open now, 2 under way, 1 of them phase 3. Of 31 finished, 25 (81%) have results posted.
Among the 35 studies in COVID-19 by BioNTech SE, this one is the 3rd largest by enrollment, is one of 10 that started in 2021, is one of 14 in phase 3, and was the 18th registered.
BioNTech SE’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing BNT162 Vaccine in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07730450BioNTech SEA Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | 2027-08-20 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing BNT162 Vaccine in COVID-19, from their registry updates:
Among BioNTech SE’s 35 in COVID-19:
This tab as a report to print or save as PDF → With an account.
Substudy A: The study will evaluate the safety, tolerability, and efficacy of a booster dose of BNT162b2 when administered to participants having previously received 2 doses of BNT162b2 at least 6 months prior to randomization.
The study is designed to describe vaccine efficacy of a booster dose of BNT162b2 over time against COVID-19
Substudy B: The study will assess the safety and tolerability of a single dose of BNT162b2 as compared to placebo control, through the potential analysis of serum troponin levels, in participants ≥12 and ≤30 years of age who have received 2 or 3 prior doses of BNT162b2 (30-µg doses) with their last dose at least 4 months (120 days) prior to randomization.
Substudy C: The study will assess the safety, tolerability, and immunogenicity of a booster (third) dose of BNT162b2 at doses of 10 µg or 30 µg in participants who have completed a 2-dose primary series of BNT162b2 (30 µg doses) at least 5 months (150 days) prior to randomization.
Substudy D: The study will assess the safety, tolerability, and immunogenicity of a 2-dose primary series of BNT162b2 OMI, and as a booster (third, fourth or fifth) dose
Participants in Cohort 3 who are COVID-19 vaccine-naïve and have not experienced COVID-19 will be enrolled to receive 2 doses (primary series) of BNT162b2 OMI, 3 weeks apart, with a dose of BNT162b2 approximately 5 months (150 days) later. If participants do not consent to receive BNT162b2 as a third dose, they will not receive a third dose. No participants should receive BNT162b2 OMI as a third dose.
Substudy E: This study will assess the safety, tolerability, and immunogenicity of high-dose BNT162b2 (60 µg), high-dose BNT162b2 OMI (60 µg), and a high-dose combination of BNT162b2 and BNT162b2 OMI at 60 µg (30 µg each), given as a single dose
Substudy F: This study will assess the safety, tolerability, and immunogenicity of high-dose BNT162b2 (60 µg), high-dose BNT162b2 OMI (60 µg), and a high-dose combination of BNT162b2 and BNT162b2 OMI at 60 µg (30 µg each), given as a single dose.
Substudy A
Inclusion Criteria:
Exclusion Criteria:
Substudy B
Inclusion Criteria:
Exclusion Criteria:
Substudy C
Inclusion Criteria:
Exclusion Criteria:
Substudy D
Inclusion Criteria:
Exclusion Criteria:
Substudy E
Inclusion Criteria:
Exclusion Criteria:
Substudy F
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 dose
Biological: BNT162b2
1 dose
Other: Placebo
1 dose
Biological: BNT162b2 · Biological: BNT162b2 OMI · Biological: Combination BNT162b2 and BNT162b2 OMI · Biological: Combination (Bivalent) BNT162b2 and BNT162b2 OMI
1 dose
Biological: BNT162b2 · Biological: BNT162b2 OMI · Biological: Combination BNT162b2 and BNT162b2 OMI · Biological: Combination (Bivalent) BNT162b2 and BNT162b2 OMI
Intramuscular Injection
Intramuscular Injection
Intramuscular Injection
30-µg (15-µg each) or 60-µg (30-µg each) Site prepared dosing suspension from 1 vial each of diluted BNT162b2 and BNT162b2 OMI Intramuscular Injection
30-µg (15-µg each) or 60-µg (30-µg each) Preformulated bivalent mixture (no dilution required) presented in a single vial Intramuscular Injection
SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population
Occurrences (number of cases) of first COVID-19 infection in participants after booster dose per 1000 person-year, without past SARS-CoV-2 infection at interim analysis were reported in this outcome measure.
Time frame: From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year [PY]) for BNT162b2 was 0.823 and for Placebo was 0.792
SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population
Occurrences (number of cases) of first COVID-19 infection in participants after booster dose with and without past SARS-CoV-2 infection at interim analysis were reported in this outcome measure.
Time frame: From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 0.871 and for Placebo was 0.835
SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Final Analysis: Evaluable Efficacy Population
Occurrences (number of cases) of first COVID-19 infection in participants after booster dose without past SARS-CoV-2 infection at final analysis were reported in this outcome measure.
Time frame: From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.098 and for Placebo was 0.932
SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection at Final Analysis: Evaluable Efficacy Population
Occurrences (number of cases) of first COVID-19 infection in participants after booster dose with and without past SARS-CoV-2 infection at final analysis were reported in this outcome measure.
Time frame: From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.173 and for Placebo was 0.989
SSA: Percentage of Participants Reporting Adverse Events
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: From booster dose (Day 1) to 1 month after booster dose
SSA: Percentage of Participants Reporting Serious Adverse Events (SAE)
An SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect; or that was considered as an important medical event.
Time frame: BNT162b2 30 mcg, Placebo then BNT162b2 30 mcg: From BNT162b2 dose to 6 months after BNT162b2 dose; Placebo: From placebo dose to unblinding for original placebo participants. Median blinded follow-up period for Placebo group=2.8 months
SSB: Percentage of Participants With Elevated Troponin I Level Pre-Dose; Vaccination 1
Percentage of participants with elevated troponin I levels before administration of Vaccination 1 were reported in this outcome measure.
Time frame: Pre-dose on Day 1 (Vaccination 1)
SSB: Percentage of Participants With Elevated Troponin I Level Within 5 Days After Vaccination 1
Percentage of participants with elevated troponin I levels within 5 days after administration of Vaccination 1 were reported in this outcome measure.
Time frame: Within 5 days after Vaccination 1
SSB: Percentage of Participants With Elevated Troponin I Level Pre-Vaccination 2 (1 Month After Vaccination 1)
Percentage of participants with elevated troponin I levels pre vaccination 2 were reported in this outcome measure.
Time frame: Pre-Vaccination 2 (1 month after Vaccination 1)
SSB: Percentage of Participants With Elevated Troponin I Level Within 5 Days After Vaccination 2
Percentage of participants with elevated troponin I levels within 5 days after administration of Vaccination 2 were reported in this outcome measure.
Time frame: Within 5 days after vaccination 2
SSB: Percentage of Participants With Elevated Troponin I Level 1 Month After Vaccination 2
Percentage of participants with elevated troponin I levels within 1 month after administration of Vaccination 2 were reported in this outcome measure.
Time frame: 1 month after Vaccination 2
SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1
Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 1 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.
Time frame: Day 1 up to Day 7 after Vaccination 1
SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2
Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 2 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.
Time frame: Day 1 up to Day 7 after Vaccination 2
SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1
Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\>=) 38.0 degree Celsius (deg C) and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 up to Day 7 after Vaccination 1
SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2
Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\>=) 38.0 degree Celsius (deg C) and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 up to Day 7 after Vaccination 2
SSB: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Vaccination 1
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after Vaccination 1 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Vaccination 1 up to 1 Month After Vaccination 1
SSB: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Vaccination 2
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Vaccination 2 up to 1 month after Vaccination 2
SSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) 1 Month After Vaccination 1
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: Vaccination 1 up to 1 month after Vaccination 1
SSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) 1 Month After Vaccination 2
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: Vaccination 2 up to 1 month after Vaccination 2
SSC: Percentage of Participants With Local Reactions Within 7 Days After Booster Dose
Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 cm and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after the booster (third) dose and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.
Time frame: Day 1 up to Day 7 after the booster dose
SSC: Percentage of Participants With Systemic Events Within 7 Days After Booster Dose
Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\>=) 38.0 degree Celsius (deg C) and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24 h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 up to Day 7 after the booster dose
SSC: Percentage of Participants Reporting Adverse Events From Booster Dose Through 1 Month After Booster Dose
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from booster (third) dose up to 1 month after booster (third) dose were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From booster dose (Day 1) up to 1 month after booster dose
SSC: Percentage of Participants Reporting Serious Adverse Events From Booster Dose Through 6 Months After Booster Dose
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From booster dose (Day 1) up to 6 months after booster dose
SSC: Geometric Mean Titers (GMT) of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Baseline
GMT of SARS-CoV-2 reference-strain-neutralizing titers at baseline (before the booster dose) was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
Time frame: At baseline (pre-dose)
SSC: GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at 1 Month After the Booster Dose
GMT of SARS-CoV-2 reference-strain-neutralizing titers at 1 month after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
Time frame: 1 month after the booster dose
SSC: Geometric Mean Fold-Rise (GMFR) of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Baseline to 1 Month After the Booster Dose
GMFR of SARS-CoV-2 reference-strain-neutralizing titers from baseline to 1 month after the booster dose received in this sub-study was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
Time frame: From baseline to 1 month after the booster dose
SSC: Percentage of Participants With Seroresponse to Reference-Strain at 1 Month After the Booster Dose
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month after the booster dose was reported in this outcome measure.
Time frame: 1 month after the booster dose
SSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1
Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu=0.5 centimeter (cm) and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection (inj) site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit/hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 1 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.
Time frame: Day 1 up to Day 7 after Vaccination 1
SSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2
Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 2 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.
Time frame: Day 1 up to Day 7 after Vaccination 2
SSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 3
Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 3 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.
Time frame: Day 1 up to Day 7 after Vaccination 3
SSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1
Systemic events were recorded in e-diary. Fever: oral temperature \>= 38.0 deg C, categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 up to Day 7 after Vaccination 1
SSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2
Systemic events were recorded in e-diary. Fever: oral temperature \>= 38.0 deg C, categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 up to Day 7 after Vaccination 2
SSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 3
Systemic events were recorded in e-diary. Fever: oral temperature \>= 38.0 deg C and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 up to Day 7 after Vaccination 3
SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Last Study Vaccination: Cohort 1
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after last study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Day 1 up to 1 month after last study vaccination
SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Vaccination 1: Cohort 2
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after Vaccination 1 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From first study vaccination (Day 1) up to 1 month after Vaccination 1
SSD: Percentage of Participants Reporting Adverse Events (AEs) From Second Study Vaccination Through 1 Month After Second Study Vaccination: Cohort 2
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from Vaccination 2 up to 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Vaccination 2 up to 1 month after Vaccination 2
SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Second Study Vaccination: Cohort 3
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From first study vaccination (Day 1) up to 1 month after Vaccination 2
SSD: Percentage of Participants Reporting Adverse Events (AEs) From Third Study Vaccination Through 1 Month After Third Study Vaccination: Cohort 3
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from Vaccination 3 up to 1 month after Vaccination 3 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Vaccination 3 up to 1 month after Vaccination 3
SSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) From First Study Vaccination (Day 1) Through 6 Months After Last Study Vaccination: Cohort 1 and Cohort 3
A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From first study vaccination (Day 1) up to 6 months after last study vaccination
SSD: Percentage of Participants Reporting SAEs From First Study Vaccination (Day 1) Through 6 Months After Vaccination 1 (For Participants Who Received 1 Dose Only) and up to Vaccination 2 (For Participants Who Received 2 Doses): Cohort 2
A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From vaccination 1 (Day 1) up to 6 months after vaccination 1 (participants received 1 dose only); From vaccination 1 up to before vaccination 2 (participants received 2 doses)
SSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) From First Study Vaccination Through 6 Months After Vaccination 2: Cohort 2
A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From first study vaccination (Day 1) up to 6 months after vaccination 2
SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After First Study Vaccination: Comparison Between Cohort 2 Group 3 and Group 4
GMR was calculated based on GMT levels of SSD: Cohort 2: Group 3 and SSD: Cohort 2: Group 4 and reported in statistical analysis section below. GMT of SARS-CoV-2 Omicron strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after first study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
Time frame: 1 month after Vaccination 1
SSD: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After First Study Vaccination: Comparison Between Cohort 2 Group 3 and Group 4
Seroresponse: achieving \>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after first study vaccination was reported in this outcome measure.
Time frame: 1 month after Vaccination 1
SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After First Study Vaccination: Comparison Between Cohort 1 Group 1 and Group 2b
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after first study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
Time frame: 1 month after Vaccination 1
SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers: Comparison Between 1 Month After Second Study Vaccination for Cohort 1 Group 2 and 1 Month After First Study Vaccination for Cohort 1 Group 2b
GMR was calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after Vaccination 2 for Group 2 and 1 month after Vaccination 1 for Group 2b was reported. GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution).
Time frame: For Cohort 1 Group 2b:1 month after Vaccination 1; for Cohort 1 Group 2: 1 month after Vaccination 2
Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After First Study Vaccination: Comparison Between Cohort 1 Group 1 and Group 2b
Seroresponse: achieving \>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after first study vaccination was reported in this outcome measure.
Time frame: 1 month after Vaccination 1
SSD: Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Vaccination 2: Comparison Between 1 Month After Vaccination 2 for Cohort 1 Group 2 and 1 Month After Vaccination 1 for Cohort 1 Group 2b
Seroresponse: achieving \>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below LLOQ, postvaccination measure of \>= 4 × LLOQ is considered seroresponse. Exact 2-sided CI, based on Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after second study vaccination for Group 2 and 1 month after study vaccination for Group 2b was reported in this outcome measure.
Time frame: For Cohort 1 Group 2b:1 month after Vaccination 1; for Cohort 1 Group 2: 1 month after Vaccination 2
SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After Second Study Vaccination: Cohort 3
GMR calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMR comparison between GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers of participants of SSD Cohort 3: Group 5 to GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers of participants of study C4591001 (NCT04368728) Phase 3 BNT162b2 single arm 18-55 years of age, at 1 month after vaccination 2 was reported. GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (student's t distribution).
Time frame: 1 month after Vaccination 2
SSD: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Second Study Vaccination: Cohort 3
EIP:eligible participants received 2 doses of study drug as randomized with Dose2 received within 19-42 days after Dose1 (SSD Cohort 3:Group 5), had valid determinate immunogenicity result from blood sample collected within 28-42 days after 2nd study vaccination, had no other important protocol deviations as determined by clinician. Data of eligible participants from Study C4591001 Phase 3 BNT162b2 single arm 18-55 years was included for comparison.'N'=participants evaluable for outcome measure.
Time frame: 1 month after Vaccination 2
SSE: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination
Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu=0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm),severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis/exfoliative dermatitis \[redness\]).Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit/hospitalization for severe pain). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions within 7 days after study vaccination and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.
Time frame: Day 1 up to Day 7 after study vaccination
SSE: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination
Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to 38.0 deg C and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C \& \>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit or hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \> 2 times in 24h, severe: required intravenous hydration and Grade 4: ER or hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit or hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 up to Day 7 after study vaccination
SSE: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From study vaccination up to 1 Month after study vaccination
SSE: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Month After Study Vaccination
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From study vaccination up to 6 Months after study vaccination
SSE: Percentage of Participants With Elevated Troponin I Levels Before the Study Vaccination- 18 to 55 Years of Age
Percentage of participants with elevated troponin I levels before study vaccination were reported in this outcome measure.
Time frame: Before study vaccination (pre-dose)
SSE: Percentage of Participants With Elevated Troponin I Levels 3 Days After Study Vaccination- 18 to 55 Years of Age
Percentage of participants with elevated troponin I levels before study vaccination were reported in this outcome measure.
Time frame: 3 days after study vaccination
SSE: Geometric Mean Ratio (GMR) Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After Study Vaccination
GMR calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
Time frame: 1 month after study vaccination
SSE: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Study Vaccination
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below lower limit of quantification (LLOQ), postvaccination measure of \>= 4 × LLOQ is considered seroresponse. Exact 2-sided CI, based on Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.
Time frame: 1 month after study vaccination
SSF: Geometric Mean Titer (GMTs) of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers Before Vaccination
GMT of SARS-CoV-2 Omicron BA.1 strain neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
Time frame: Before vaccination (pre-dose)
SSF: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination
Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (necrosis \[swelling\] or necrosis/exfoliative dermatitis \[redness\]). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after study vaccination and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.
Time frame: Day 1 up to Day 7 after the study vaccination
SSF: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination
Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to 38.0 deg C and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C \& \>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit or hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \> 2 times in 24h, severe: required intravenous hydration and Grade 4: ER or hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit or hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 up to Day 7 after the study vaccination
SSF: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From study vaccination up to 1 Month after study vaccination
SSF: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Months After Study Vaccination
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From study vaccination up to 6 Months after study vaccination
SSF: GMTs of SARS-CoV-2 Reference-Strain-Neutralizing Titers Before Vaccination
GMT of SARS-CoV-2 reference-strain-neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
Time frame: Before vaccination (pre-dose)
SSF: GMTs of SARS-CoV-2 Omicron BA.4/BA.5 Strain Neutralizing Titers Before Vaccination
GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
Time frame: Before vaccination (pre-dose)
SSF: Geometric Mean Ratio (GMR) Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Day 7
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Day 7 (7 days after vaccination)
SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Day 7
GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Day 7 (7 days after vaccination)
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain Neutralizing Titers at Day 7
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Day 7 (7 days after vaccination)
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 1
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Month 1 (1 month after vaccination)
SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 1
GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Month 1 (1 month after vaccination)
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 1
GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Month 1 (1 month after vaccination)
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 3
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Month 3 (3 month after vaccination)
SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 3
GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Month 3 (3 month after vaccination)
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 3
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Month 3 (3 month after vaccination)
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 6
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Month 6 (6 month after vaccination)
SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 6
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Month 6 (6 months after vaccination)
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 6
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Month 6 (6 months after vaccination)
SSF: Geometric Mean Fold-Rise (GMFR) of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination
GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
Time frame: From before the study vaccination to Day 7 (7 days after vaccination)
SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination
GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
Time frame: From before the study vaccination to Day 7 (7 days after vaccination)
SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination
GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
Time frame: From before the study vaccination to Day 7 (7 days after vaccination)
SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination
GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
Time frame: From before the study vaccination to 1 month after vaccination
SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination
GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
Time frame: From before the study vaccination to 1 month after vaccination
SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination
GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
Time frame: From before the study vaccination to 1 month after vaccination
SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination
GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
Time frame: From before the study vaccination to 3 months after vaccination
SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination
GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
Time frame: From before the study vaccination to 3 months after vaccination
SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination
GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
Time frame: From before the study vaccination to 3 months after vaccination
SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination
GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
Time frame: From before the study vaccination to 6 months after vaccination
SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination
GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
Time frame: From before the study vaccination to 6 months after vaccination
SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination
GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
Time frame: From before the study vaccination to 6 months after vaccination
SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Day 7
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.
Time frame: Day 7 (7 days after vaccination)
SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Day 7
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.
Time frame: Day 7 (7 days after vaccination)
SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Day 7
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.
Time frame: Day 7 (7 days after vaccination)
SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 1
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.
Time frame: Month 1 (1 month after vaccination)
SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 1
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.
Time frame: Month 1 (1 month after vaccination)
SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 1
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.
Time frame: Month 1 (1 month after vaccination)
SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 3
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.
Time frame: Month 3 (3 months after vaccination)
SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 3
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.
Time frame: Month 3 (3 months after vaccination)
SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 3
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.
Time frame: Month 3 (3 months after vaccination)
SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 6
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.
Time frame: Month 6 (6 months after vaccination)
SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 6
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.
Time frame: Month 6 (6 months after vaccination)
SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 6
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.
Time frame: Month 6 (6 months after vaccination)
SSA: Occurrence of First Severe COVID-19 Infection (FDA Definition) Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection: Evaluable Efficacy Population
Occurrence (number of cases) of first severe COVID-19 infection based on FDA definition after booster dose without past SARS-CoV-2 infection is reported. FDA definition: confirmed COVID-19 and presence of at least 1 of the following: 1) clinical signs at rest indicative of severe systemic illness (respiratory rate greater than or equal to \[\>=\]30 breaths per minute, heart rate \>= 125 beats per minute, oxygen saturation less than or equal to \[\<=\]93% on room air at sea level, or Horovitz quotient \<300 mmHg); 2) respiratory failure (needing high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation); 3) evidence of shock (systolic blood pressure \[BP\] \<90 mmHg, diastolic BP \<60 mmHg, or requiring vasopressors); 4) significant acute renal, hepatic, or neurologic dysfunction; 5) admission to an intensive care unit; 6) death.
Time frame: From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.105 and for Placebo was 0.951
SSA: Occurrence of First Severe COVID-19 Infection (FDA Definition) Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection: Evaluable Efficacy Population
Occurrence (number of cases) of first severe COVID-19 infection based on FDA definition after booster dose with and without past SARS-CoV-2 infection is reported. FDA definition: confirmed COVID-19 and presence of at least 1 of the following: 1) clinical signs at rest indicative of severe systemic illness (respiratory rate \>= 30 breaths per minute, heart rate \>= 125 beats per minute, oxygen saturation \<= 93% on room air at sea level, or Horovitz quotient \<300 mm Hg); 2) respiratory failure (defined as needing high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation); 3) evidence of shock (systolic BP \<90 mm Hg, diastolic BP \<60 mm Hg, or requiring vasopressors); 4) significant acute renal, hepatic, or neurologic dysfunction; 5) admission to an intensive care unit; 6) death.
Time frame: From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.182 and for Placebo was 1.011
SSA: Occurrence of First Severe COVID-19 Infection (CDC Definition) Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection
Occurrence (number of cases) of first severe COVID-19 infection based on CDC definition after booster dose without past SARS-CoV-2 infection is reported. CDC definition: confirmed COVID-19 and presence of at least 1 of the following: 1) hospitalization; 2) admission to an intensive care unit; 3) intubation or mechanical ventilation; 4) death.
Time frame: From 7 Days after booster vaccination
SSA: Occurrence of First Severe COVID-19 Infection (CDC Definition) Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection
Occurrence (number of cases) of first severe COVID-19 infection based on CDC definition after booster dose with and without past SARS-CoV-2 infection is reported. CDC definition: confirmed COVID-19 AND presence of at least 1 of the following: 1) hospitalization; 2) admission to an intensive care unit; 3) intubation or mechanical ventilation; 4) death.
Time frame: From 7 Days after booster vaccination
SSC: GMTs of SARS-CoV-2 Reference-Strain Neutralizing Titers at Baseline and 7 Days After the Booster Dose
GMT of SARS-CoV-2 reference-strain neutralizing titers at baseline and 7 days after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
Time frame: At baseline and 7 days after the booster dose
SSC: GMTs of SARS-CoV-2 Omicron BA.1- Neutralizing Titers at Baseline and 7 Days After the Booster Dose
GMT of SARS-CoV-2 Omicron BA.1- neutralizing titers at baseline and 7 days after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
Time frame: At baseline and 7 days after booster dose
SSC: GMFRs of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Baseline to 7 Days After the Booster Dose
GMFR of SARS-CoV-2 reference-strain-neutralizing titers from baseline (before the booster dose) to 7 days after the booster dose was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
Time frame: From baseline (before booster dose) to 7 days after the booster dose
SSC: GMFRs of SARS-CoV-2 Omicron BA.1-Neutralizing Titers From Baseline to 7 Days After the Booster Dose
GMFR of SARS-CoV-2 Omicron BA.1-strain-neutralizing titers from baseline (before the booster dose) to 7 days after the booster dose was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
Time frame: From baseline (before booster dose) to 7 days after the booster dose
SSC: Percentages of Participants With Seroresponse to Reference Strain at 7 Days After the Booster Dose
Seroresponse was defined as achieving \>= 4-fold rise from before booster dose. If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse to reference strain at 7 days after the booster dose was reported in this outcome measure.
Time frame: 7 days after the booster dose
SSC: Percentages of Participants With Seroresponse to Omicron BA.1 at 7 Days After the Booster Dose
Seroresponse was defined as achieving \>= 4-fold rise from before booster dose. If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse to Omicron BA.1 strain at 7 days after the booster dose was reported in this outcome measure.
Time frame: 7 days after the booster dose
SSE: GMR Based on Geometric Mean Titers of SARS-CoV-2 Reference Strain Neutralizing Titers at 1 Month After the Study Vaccination- >55 Years of Age
GMR based on GMT of SARS-CoV-2 reference strain neutralizing titers was calculated and reported in statistical analysis section. GMT of SARS-CoV-2 Reference strain-neutralizing titers at 1 month after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
Time frame: 1 month after study vaccination
This study was conducted in 6 parts: sub-study A (SSA), sub-study B (SSB), sub-study C (SSC), sub-study D (SSD), sub-study E (SSE) and sub-study F (SSF).
| Milestone | SSA: BNT162b2 30 mcg: Blinded and Open Label Period | SSA: Placebo: Blinded Period, Then BNT162b2 30 mcg Open-Label Period | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg | SSD: Cohort 1: Group 1 | SSD: Cohort 1: Group 2 | SSD: Cohort 1: Group 2b | SSD: Cohort 2: Group 3 | SSD: Cohort 2: Group 4 | SSD: Cohort 3: Group 5 | SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg | SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 5080 | 5041 | 753 | 732 | 75 | 65 | 216 | 197 | 204 | 315 | 325 | 210 | 30 | 30 | 30 | 482 | 159 | 321 | 20 | 20 | 20 | 20 | 20 | 20 | 305 | 302 | 307 | 307 | 308 | 313 | 21 | 19 | 21 | 20 | 20 | 21 |
| Safety analysis set | 5080 | 5041 | 753 | 732 | 75 | 65 | 216 | 197 | 204 | 315 | 323 | 210 | 30 | 30 | 30 | 482 | 159 | 321 | 20 | 20 | 20 | 20 | 20 | 20 | 305 | 302 | 307 | 307 | 308 | 313 | 21 | 19 | 21 | 20 | 20 | 21 |
| Completed | 421 | 22 | 726 | 693 | 69 | 58 | 197 | 183 | 193 | 286 | 293 | 159 | 28 | 30 | 27 | 450 | 151 | 302 | 19 | 19 | 19 | 19 | 20 | 19 | 292 | 294 | 291 | 299 | 294 | 307 | 21 | 19 | 21 | 20 | 20 | 21 |
| Not completed | 4659 | 5019 | 27 | 39 | 6 | 7 | 19 | 14 | 11 | 29 | 32 | 51 | 2 | 0 | 3 | 32 | 8 | 19 | 1 | 1 | 1 | 1 | 0 | 1 | 13 | 8 | 16 | 8 | 14 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 28 | 28 | 7 | 14 | 3 | 2 | 6 | 4 | 5 | 8 | 10 | 32 | 0 | 0 | 0 | 12 | 2 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 5 | 14 | 0 | 1 | 2 | 2 | 0 | 0 | 0 | 4 | 6 | 1 | 0 | 0 | 2 | 6 | 4 | 6 | 0 | 1 | 0 | 1 | 0 | 0 | 4 | 6 | 5 | 3 | 4 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: No longer meets eligibility criteria | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 3 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 54 | 3 | 4 | 2 | 0 | 0 | 2 | 2 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 | 3 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 26 | 62 | 14 | 16 | 1 | 2 | 9 | 5 | 3 | 15 | 11 | 7 | 2 | 0 | 1 | 11 | 2 | 5 | 0 | 0 | 1 | 0 | 0 | 0 | 5 | 1 | 5 | 1 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Refused further study procedures | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participants entered open label period | 4544 | 4906 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Medication error | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | SSA: BNT162b2 30 mcg: Blinded and Open Label Period | SSA: Placebo: Blinded Period, Then BNT162b2 30 mcg Open-Label Period | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg | SSD: Cohort 1: Group 1 | SSD: Cohort 1: Group 2 | SSD: Cohort 1: Group 2b | SSD: Cohort 2: Group 3 | SSD: Cohort 2: Group 4 | SSD: Cohort 3: Group 5 | SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg | SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4544 | 4906 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received open-label bnt162b2 30 mcg | 4544 | 4430 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 3272 | 3878 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1272 | 1028 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 109 | 41 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 377 | 48 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: No longer meets eligibility criteria | 20 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 621 | 429 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 135 | 25 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Refused further study procedures | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Did not receive open-label bnt162b2 30 mcg | 0 | 476 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Occurrences (number of cases) of first COVID-19 infection in participants after booster dose per 1000 person-year, without past SARS-CoV-2 infection at interim analysis were reported in this outcome measure.
| Number of first Covid-19 cases/1000 PY | SSA: BNT162b2 30 mcg: Blinded and Open Label Period | SSA: Placebo: Blinded Period |
|---|---|---|
| SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population | 7.290 | 155.303 |
Occurrences (number of cases) of first COVID-19 infection in participants after booster dose with and without past SARS-CoV-2 infection at interim analysis were reported in this outcome measure.
| Number of first Covid-19 cases/1000 PY | SSA: BNT162b2 30 mcg: Blinded and Open Label Period | SSA: Placebo: Blinded Period |
|---|---|---|
| SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population | 8.037 | 148.503 |
Occurrences (number of cases) of first COVID-19 infection in participants after booster dose without past SARS-CoV-2 infection at final analysis were reported in this outcome measure.
| Number of first Covid-19 cases/1000 PY | SSA: BNT162b2 30 mcg: Blinded and Open Label Period | SSA: Placebo: Blinded Period |
|---|---|---|
| SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Final Analysis: Evaluable Efficacy Population | 57.377 | 158.798 |
Occurrences (number of cases) of first COVID-19 infection in participants after booster dose with and without past SARS-CoV-2 infection at final analysis were reported in this outcome measure.
| Number of first Covid-19 cases/1000 PY | SSA: BNT162b2 30 mcg: Blinded and Open Label Period | SSA: Placebo: Blinded Period |
|---|---|---|
| SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection at Final Analysis: Evaluable Efficacy Population | 57.118 | 151.668 |
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Percentage of participants | SSA: BNT162b2 30 mcg: Blinded and Open Label Period | SSA: Placebo: Blinded Period |
|---|---|---|
| SSA: Percentage of Participants Reporting Adverse Events | 26.3 (25.0 to 27.5) | 7.1 (6.4 to 7.8) |
An SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect; or that was considered as an important medical event.
| Percentage of participants | SSA: BNT162b2 30 mcg: Blinded and Open Label Period | SSA: Placebo: Blinded Period | SSA: Original Placebo/BNT162b2 30 mcg: Open Label Period |
|---|---|---|---|
| SSA: Percentage of Participants Reporting Serious Adverse Events (SAE) | 1.4 (1.1 to 1.8) | 0.8 (0.6 to 1.1) | 1.0 (0.7 to 1.3) |
Percentage of participants with elevated troponin I levels before administration of Vaccination 1 were reported in this outcome measure.
| Percentage of participants | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg |
|---|---|---|
| SSB: Percentage of Participants With Elevated Troponin I Level Pre-Dose; Vaccination 1 | 0.7 (0.2 to 1.5) | 0.5 (0.1 to 1.4) |
Percentage of participants with elevated troponin I levels within 5 days after administration of Vaccination 1 were reported in this outcome measure.
| Percentage of participants | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg |
|---|---|---|
| SSB: Percentage of Participants With Elevated Troponin I Level Within 5 Days After Vaccination 1 | 1.0 (0.4 to 2.0) | 0.6 (0.2 to 1.5) |
Percentage of participants with elevated troponin I levels pre vaccination 2 were reported in this outcome measure.
| Percentage of participants | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg |
|---|---|---|
| SSB: Percentage of Participants With Elevated Troponin I Level Pre-Vaccination 2 (1 Month After Vaccination 1) | 1.1 (0.4 to 2.3) | 0.3 (0.0 to 1.2) |
Percentage of participants with elevated troponin I levels within 5 days after administration of Vaccination 2 were reported in this outcome measure.
| Percentage of participants | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg |
|---|---|---|
| SSB: Percentage of Participants With Elevated Troponin I Level Within 5 Days After Vaccination 2 | 1.5 (0.7 to 2.7) | 0.3 (0.0 to 1.1) |
Percentage of participants with elevated troponin I levels within 1 month after administration of Vaccination 2 were reported in this outcome measure.
| Percentage of participants | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg |
|---|---|---|
| SSB: Percentage of Participants With Elevated Troponin I Level 1 Month After Vaccination 2 | 0.7 (0.2 to 1.7) | 0.3 (0.0 to 1.1) |
Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 1 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.
| Percentage of participants | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg |
|---|---|---|
| Redness: Any | 5.8 (4.2 to 7.7) | 0.5 (0.1 to 1.4) |
| Redness: Mild | 4.4 (3.1 to 6.1) | 0.4 (0.1 to 1.2) |
| Redness: Moderate | 1.1 (0.5 to 2.1) | 0.1 (0.0 to 0.8) |
| Redness: Severe | 0.3 (0.0 to 1.0) | 0 (0.0 to 0.5) |
| Redness: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Swelling: Any | 6.6 (4.9 to 8.6) | 0.5 (0.1 to 1.4) |
| Swelling: Mild | 5.0 (3.5 to 6.8) | 0.4 (0.1 to 1.2) |
| Swelling: Moderate | 1.5 (0.7 to 2.6) | 0 (0.0 to 0.5) |
| Swelling: Severe | 0.1 (0.0 to 0.7) | 0.1 (0.0 to 0.8) |
| Swelling: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Pain at injection site: Any | 74.4 (71.1 to 77.5) | 13.9 (11.4 to 16.6) |
| Pain at injection site: Mild | 48.7 (45.1 to 52.4) | 12.2 (9.9 to 14.8) |
| Pain at injection site: Moderate | 25.4 (22.3 to 28.7) | 1.6 (0.9 to 2.9) |
| Pain at injection site: Severe | 0.3 (0.0 to 1.0) | 0 (0.0 to 0.5) |
| Pain at injection site: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 2 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.
| Percentage of participants | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg |
|---|---|---|
| Redness: Any | 0.7 (0.2 to 1.6) | 4.6 (3.2 to 6.5) |
| Redness: Mild | 0.3 (0.0 to 1.0) | 2.8 (1.7 to 4.4) |
| Redness: Moderate | 0.4 (0.1 to 1.2) | 1.5 (0.7 to 2.7) |
| Redness: Severe | 0 (0.0 to 0.5) | 0.3 (0.0 to 1.1) |
| Redness: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Swelling: Any | 0.4 (0.1 to 1.2) | 5.5 (3.9 to 7.5) |
| Swelling: Mild | 0.4 (0.1 to 1.2) | 3.4 (2.2 to 5.1) |
| Swelling: Moderate | 0 (0.0 to 0.5) | 1.9 (1.0 to 3.3) |
| Swelling: Severe | 0 (0.0 to 0.5) | 0.1 (0.0 to 0.8) |
| Swelling: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Pain at injection site: Any | 8.8 (6.8 to 11.1) | 71.7 (68.2 to 75.1) |
| Pain at injection site: Mild | 6.7 (4.9 to 8.8) | 40.3 (36.6 to 44.1) |
| Pain at injection site: Moderate | 2.1 (1.2 to 3.5) | 30.5 (27.0 to 34.1) |
| Pain at injection site: Severe | 0 (0.0 to 0.5) | 0.9 (0.3 to 1.9) |
| Pain at injection site: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\>=) 38.0 degree Celsius (deg C) and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.
| Percentage of participants | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg |
|---|---|---|
| Fever: >=38 deg C | 6.0 (4.4 to 8.0) | 1.9 (1.1 to 3.2) |
| Fever: 38.0 to 38.4 deg C | 4.1 (2.8 to 5.8) | 1.4 (0.7 to 2.5) |
| Fever: >38.4 to 38.9 deg C | 1.7 (0.9 to 3.0) | 0.3 (0.0 to 1.0) |
| Fever: >38.9 to 40.0 deg C | 0.1 (0.0 to 0.7) | 0.3 (0.0 to 1.0) |
| Fever: >40.0 deg C | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Fatigue: Any | 54.2 (50.6 to 57.8) | 31.9 (28.5 to 35.4) |
| Fatigue: Mild | 27.4 (24.3 to 30.8) | 19.5 (16.7 to 22.6) |
| Fatigue: Moderate | 25.3 (22.2 to 28.6) | 12.2 (9.9 to 14.8) |
| Fatigue: Severe | 1.5 (0.7 to 2.6) | 0.1 (0.0 to 0.8) |
| Fatigue: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Headache: Any | 42.6 (39.0 to 46.2) | 28.3 (25.0 to 31.7) |
| Headache: Mild | 24.2 (21.2 to 27.5) | 18.0 (15.3 to 21.0) |
| Headache: Moderate | 17.3 (14.6 to 20.2) | 10.0 (7.9 to 12.4) |
| Headache: Severe | 1.1 (0.5 to 2.1) | 0.3 (0.0 to 1.0) |
| Headache: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Chills: Any | 17.1 (14.5 to 20.0) | 5.9 (4.3 to 7.9) |
| Chills: Mild | 10.6 (8.5 to 13.0) | 4.4 (3.0 to 6.1) |
| Chills: Moderate | 6.3 (4.7 to 8.3) | 1.5 (0.8 to 2.7) |
| Chills: Severe | 0.3 (0.0 to 1.0) | 0 (0.0 to 0.5) |
| Chills: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Vomiting: Any | 3.2 (2.1 to 4.7) | 0.8 (0.3 to 1.8) |
| Vomiting: Mild | 2.8 (1.7 to 4.3) | 0.7 (0.2 to 1.6) |
| Vomiting: Moderate | 0.4 (0.1 to 1.2) | 0.1 (0.0 to 0.8) |
| Vomiting: Severe | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Vomiting: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Diarrhea: Any | 7.4 (5.6 to 9.5) | 7.4 (5.6 to 9.6) |
| Diarrhea: Mild | 6.4 (4.8 to 8.4) | 6.0 (4.4 to 8.0) |
| Diarrhea: Moderate | 0.9 (0.4 to 1.9) | 1.4 (0.7 to 2.5) |
| Diarrhea: Severe | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Diarrhea: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| New or worsened muscle pain: Any | 27.6 (24.4 to 30.9) | 7.7 (5.9 to 9.9) |
| New or worsened muscle pain: Mild | 14.1 (11.6 to 16.8) | 5.1 (3.6 to 6.9) |
| New or worsened muscle pain: Moderate | 13.3 (10.9 to 15.9) | 2.5 (1.5 to 3.9) |
| New or worsened muscle pain: Severe | 0.3 (0.0 to 1.0) | 0.1 (0.0 to 0.8) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| New or worsened joint pain: Any | 12.9 (10.5 to 15.5) | 4.5 (3.1 to 6.3) |
| New or worsened joint pain: Mild | 8.3 (6.4 to 10.5) | 3.0 (1.9 to 4.5) |
| New or worsened joint pain: Moderate | 4.3 (2.9 to 6.0) | 1.5 (0.8 to 2.7) |
| New or worsened joint pain: Severe | 0.3 (0.0 to 1.0) | 0 (0.0 to 0.5) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\>=) 38.0 degree Celsius (deg C) and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.
| Percentage of participants | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg |
|---|---|---|
| Fever: >=38 deg C | 0.4 (0.1 to 1.2) | 4.3 (2.9 to 6.1) |
| Fever: 38.0 to 38.4 deg C | 0.3 (0.0 to 1.0) | 2.5 (1.5 to 4.0) |
| Fever: >38.4 to 38.9 deg C | 0.1 (0.0 to 0.8) | 1.3 (0.6 to 2.5) |
| Fever: >38.9 to 40.0 deg C | 0 (0.0 to 0.5) | 0.4 (0.1 to 1.3) |
| Fever: >40.0 deg C | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Fatigue: Any | 17.6 (14.8 to 20.6) | 47.3 (43.5 to 51.2) |
| Fatigue: Mild | 8.6 (6.7 to 11.0) | 18.8 (15.9 to 21.9) |
| Fatigue: Moderate | 8.5 (6.5 to 10.8) | 27.1 (23.8 to 30.6) |
| Fatigue: Severe | 0.4 (0.1 to 1.2) | 1.5 (0.7 to 2.7) |
| Fatigue: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Headache: Any | 17.8 (15.1 to 20.9) | 39.7 (36.0 to 43.5) |
| Headache: Mild | 10.3 (8.2 to 12.8) | 19.8 (16.8 to 23.0) |
| Headache: Moderate | 7.2 (5.4 to 9.4) | 19.0 (16.1 to 22.2) |
| Headache: Severe | 0.3 (0.0 to 1.0) | 0.9 (0.3 to 1.9) |
| Headache: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Chills: Any | 3.7 (2.4 to 5.3) | 22.3 (19.2 to 25.7) |
| Chills: Mild | 2.3 (1.3 to 3.7) | 13.2 (10.8 to 16.0) |
| Chills: Moderate | 1.1 (0.5 to 2.2) | 8.8 (6.8 to 11.2) |
| Chills: Severe | 0.3 (0.0 to 1.0) | 0.3 (0.0 to 1.1) |
| Chills: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Vomiting: Any | 1.0 (0.4 to 2.0) | 1.9 (1.0 to 3.3) |
| Vomiting: Mild | 0.7 (0.2 to 1.6) | 1.8 (0.9 to 3.1) |
| Vomiting: Moderate | 0.3 (0.0 to 1.0) | 0.1 (0.0 to 0.8) |
| Vomiting: Severe | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Vomiting: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Diarrhea: Any | 3.3 (2.1 to 4.8) | 8.0 (6.1 to 10.4) |
| Diarrhea: Mild | 2.1 (1.2 to 3.5) | 6.5 (4.8 to 8.7) |
| Diarrhea: Moderate | 1.1 (0.5 to 2.2) | 1.5 (0.7 to 2.7) |
| Diarrhea: Severe | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| Diarrhea: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| New or worsened muscle pain: Any | 4.5 (3.1 to 6.3) | 29.2 (25.8 to 32.8) |
| New or worsened muscle pain: Mild | 2.3 (1.3 to 3.7) | 15.9 (13.2 to 18.9) |
| New or worsened muscle pain: Moderate | 2.1 (1.2 to 3.5) | 12.9 (10.5 to 15.7) |
| New or worsened muscle pain: Severe | 0.1 (0.0 to 0.8) | 0.3 (0.0 to 1.1) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| New or worsened joint pain: Any | 3.1 (2.0 to 4.7) | 12.2 (9.8 to 14.9) |
| New or worsened joint pain: Mild | 1.6 (0.8 to 2.8) | 7.4 (5.6 to 9.7) |
| New or worsened joint pain: Moderate | 1.6 (0.8 to 2.8) | 4.8 (3.3 to 6.7) |
| New or worsened joint pain: Severe | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 0.5) | 0 (0.0 to 0.5) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after Vaccination 1 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg |
|---|---|---|
| SSB: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Vaccination 1 | 9.4 (7.4 to 11.7) | 10.4 (8.3 to 12.8) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg |
|---|---|---|
| SSB: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Vaccination 2 | 5.6 (4.1 to 7.5) | 7.4 (5.6 to 9.6) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg |
|---|---|---|
| SSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) 1 Month After Vaccination 1 | 0.1 (0.0 to 0.7) | 0.3 (0.0 to 1.0) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg |
|---|---|---|
| SSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) 1 Month After Vaccination 2 | 0 (0.0 to 0.5) | 0.1 (0.0 to 0.8) |
Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 cm and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after the booster (third) dose and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.
| Percentage of participants | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg |
|---|---|---|
| Redness: Any | 1.3 (0.0 to 7.2) | 6.3 (1.7 to 15.2) |
| Redness: Mild | 1.3 (0.0 to 7.2) | 4.7 (1.0 to 13.1) |
| Redness: Moderate | 0 (0.0 to 4.8) | 1.6 (0.0 to 8.4) |
| Redness: Severe | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
| Redness: Grade 4 | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
| Swelling: Any | 2.7 (0.3 to 9.3) | 9.4 (3.5 to 19.3) |
| Swelling: Mild | 2.7 (0.3 to 9.3) | 6.3 (1.7 to 15.2) |
| Swelling: Moderate | 0 (0.0 to 4.8) | 3.1 (0.4 to 10.8) |
| Swelling: Severe | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
| Swelling: Grade 4 | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
| Pain at the injection site: Any | 56.0 (44.1 to 67.5) | 78.1 (66.0 to 87.5) |
| Pain at the injection site: Mild | 40.0 (28.9 to 52.0) | 46.9 (34.3 to 59.8) |
| Pain at the injection site: Moderate | 16.0 (8.6 to 26.3) | 31.3 (20.2 to 44.1) |
| Pain at the injection site: Severe | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\>=) 38.0 degree Celsius (deg C) and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24 h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.
| Percentage of participants | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg |
|---|---|---|
| Fever: >=38.0 deg C | 4.0 (0.8 to 11.2) | 6.3 (1.7 to 15.2) |
| Fever: >=38.0°C to 38.4 deg C | 2.7 (0.3 to 9.3) | 3.1 (0.4 to 10.8) |
| Fever: >38.4°C to 38.9 deg C | 0 (0.0 to 4.8) | 1.6 (0.0 to 8.4) |
| Fever: >38.9°C to 40.0 deg C | 1.3 (0.0 to 7.2) | 0 (0.0 to 5.6) |
| Fever: >40.0 deg C | 0 (0.0 to 4.8) | 1.6 (0.0 to 8.4) |
| Fatigue: Any | 49.3 (37.6 to 61.1) | 54.7 (41.7 to 67.2) |
| Fatigue: Mild | 22.7 (13.8 to 33.8) | 25.0 (15.0 to 37.4) |
| Fatigue: Moderate | 25.3 (16.0 to 36.7) | 26.6 (16.3 to 39.1) |
| Fatigue: Severe | 1.3 (0.0 to 7.2) | 3.1 (0.4 to 10.8) |
| Fatigue: Grade 4 | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
| Headache: Any | 41.3 (30.1 to 53.3) | 53.1 (40.2 to 65.7) |
| Headache: Mild | 21.3 (12.7 to 32.3) | 31.3 (20.2 to 44.1) |
| Headache: Moderate | 20.0 (11.6 to 30.8) | 20.3 (11.3 to 32.2) |
| Headache: Severe | 0 (0.0 to 4.8) | 1.6 (0.0 to 8.4) |
| Headache: Grade 4 | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
| Chills: Any | 13.3 (6.6 to 23.2) | 23.4 (13.8 to 35.7) |
| Chills: Mild | 5.3 (1.5 to 13.1) | 12.5 (5.6 to 23.2) |
| Chills: Moderate | 8.0 (3.0 to 16.6) | 10.9 (4.5 to 21.2) |
| Chills: Severe | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
| Chills: Grade 4 | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
| Vomiting: Any | 1.3 (0.0 to 7.2) | 3.1 (0.4 to 10.8) |
| Vomiting: Mild | 0 (0.0 to 4.8) | 1.6 (0.0 to 8.4) |
| Vomiting: Moderate | 1.3 (0.0 to 7.2) | 1.6 (0.0 to 8.4) |
| Vomiting: Severe | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
| Vomiting: Grade 4 | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
| Diarrhea: Any | 4.0 (0.8 to 11.2) | 9.4 (3.5 to 19.3) |
| Diarrhea: Mild | 2.7 (0.3 to 9.3) | 9.4 (3.5 to 19.3) |
| Diarrhea: Moderate | 1.3 (0.0 to 7.2) | 0 (0.0 to 5.6) |
| Diarrhea: Severe | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
| Diarrhea: Grade 4 | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
| New or worsened muscle pain: Any | 24.0 (14.9 to 35.3) | 37.5 (25.7 to 50.5) |
| New or worsened muscle pain: Mild | 4.0 (0.8 to 11.2) | 20.3 (11.3 to 32.2) |
| New or worsened muscle pain: Moderate | 20.0 (11.6 to 30.8) | 17.2 (8.9 to 28.7) |
| New or worsened muscle pain: Severe | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
| New or worsened joint pain: Any | 14.7 (7.6 to 24.7) | 15.6 (7.8 to 26.9) |
| New or worsened joint pain: Mild | 5.3 (1.5 to 13.1) | 10.9 (4.5 to 21.2) |
| New or worsened joint pain: Moderate | 9.3 (3.8 to 18.3) | 4.7 (1.0 to 13.1) |
| New or worsened joint pain: Severe | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 4.8) | 0 (0.0 to 5.6) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from booster (third) dose up to 1 month after booster (third) dose were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg |
|---|---|---|
| SSC: Percentage of Participants Reporting Adverse Events From Booster Dose Through 1 Month After Booster Dose | 4.0 (0.8 to 11.2) | 7.7 (2.5 to 17.0) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg |
|---|---|---|
| SSC: Percentage of Participants Reporting Serious Adverse Events From Booster Dose Through 6 Months After Booster Dose | 0 (0.0 to 4.8) | 1.5 (0.0 to 8.3) |
GMT of SARS-CoV-2 reference-strain-neutralizing titers at baseline (before the booster dose) was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
| Titer | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg |
|---|---|---|
| SSC: Geometric Mean Titers (GMT) of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Baseline | 1337.2 (941.5 to 1899.2) | 1648.4 (1087.5 to 2498.6) |
GMT of SARS-CoV-2 reference-strain-neutralizing titers at 1 month after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
| Titer | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg |
|---|---|---|
| SSC: GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at 1 Month After the Booster Dose | 11672.4 (9754.8 to 13967.0) | 15680.7 (13308.9 to 18475.2) |
GMFR of SARS-CoV-2 reference-strain-neutralizing titers from baseline to 1 month after the booster dose received in this sub-study was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
| Fold rise | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg |
|---|---|---|
| SSC: Geometric Mean Fold-Rise (GMFR) of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Baseline to 1 Month After the Booster Dose | 8.6 (6.4 to 11.6) | 9.5 (6.5 to 13.9) |
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month after the booster dose was reported in this outcome measure.
| Percentage of participants | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg |
|---|---|---|
| SSC: Percentage of Participants With Seroresponse to Reference-Strain at 1 Month After the Booster Dose | 67.7 (54.9 to 78.8) | 66.7 (52.5 to 78.9) |
Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu=0.5 centimeter (cm) and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection (inj) site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit/hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 1 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.
| Percentage of participants | SSD: Cohort 1: Group 1 | SSD: Cohort 1: Group 2 | SSD: Cohort 1: Group 2b | SSD: Cohort 2: Group 3 | SSD: Cohort 2: Group 4 | SSD: Cohort 3: Group 5 |
|---|---|---|---|---|---|---|
| Redness: Any | 3.4 (1.4 to 6.8) | 5.7 (2.9 to 10.0) | 2.5 (0.8 to 5.7) | 7.1 (4.5 to 10.7) | 4.3 (2.3 to 7.2) | 5.4 (2.6 to 9.7) |
| Redness: Mild | 1.0 (0.1 to 3.4) | 4.2 (1.8 to 8.0) | 1.0 (0.1 to 3.5) | 4.4 (2.4 to 7.4) | 3.9 (2.1 to 6.8) | 3.2 (1.2 to 6.9) |
| Redness: Moderate | 1.4 (0.3 to 4.2) | 1.6 (0.3 to 4.5) | 1.5 (0.3 to 4.3) | 2.7 (1.2 to 5.3) | 0.3 (0.0 to 1.8) | 2.2 (0.6 to 5.4) |
| Redness: Severe | 1.0 (0.1 to 3.4) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 2.0) |
| Redness: Grade 4 | 0 (0.0 to 1.8) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 2.0) |
| Swelling: Any | 8.2 (4.9 to 12.8) | 7.3 (4.0 to 11.9) | 5.5 (2.8 to 9.6) | 8.5 (5.6 to 12.3) | 8.9 (5.9 to 12.7) | 11.3 (7.1 to 16.7) |
| Swelling: Mild | 4.3 (2.0 to 8.1) | 4.2 (1.8 to 8.0) | 4.5 (2.1 to 8.3) | 5.4 (3.1 to 8.7) | 6.9 (4.3 to 10.4) | 6.5 (3.4 to 11.0) |
| Swelling: Moderate | 3.9 (1.7 to 7.5) | 2.6 (0.9 to 6.0) | 1.0 (0.1 to 3.5) | 3.1 (1.4 to 5.7) | 2.0 (0.7 to 4.2) | 4.8 (2.2 to 9.0) |
| Swelling: Severe | 0 (0.0 to 1.8) | 0.5 (0.0 to 2.9) | 0 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 2.0) |
| Swelling: Grade 4 | 0 (0.0 to 1.8) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 2.0) |
| Injection site pain: Any | 46.4 (39.4 to 53.4) | 42.7 (35.6 to 50.0) | 42.3 (35.4 to 49.4) | 78.2 (73.1 to 82.8) | 78.9 (73.9 to 83.4) | 54.3 (46.8 to 61.5) |
| Injection site pain: Mild | 30.9 (24.7 to 37.7) | 27.1 (20.9 to 34.0) | 32.3 (25.9 to 39.3) | 59.2 (53.3 to 64.9) | 61.5 (55.8 to 67.0) | 27.7 (21.4 to 34.6) |
| Injection site pain: Moderate | 15.0 (10.4 to 20.6) | 14.1 (9.5 to 19.8) | 9.5 (5.8 to 14.4) | 18.4 (14.1 to 23.3) | 16.4 (12.5 to 21.1) | 26.1 (19.9 to 33.0) |
| Injection site pain: Severe | 0.5 (0.0 to 2.7) | 1.6 (0.3 to 4.5) | 0.5 (0.0 to 2.7) | 0.7 (0.1 to 2.4) | 1.0 (0.2 to 2.9) | 0.5 (0.0 to 2.9) |
| Injection site pain: Grade 4 | 0 (0.0 to 1.8) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.9) |
Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 2 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.
| Percentage of participants | SSD: Cohort 1: Group 2 | SSD: Cohort 2: Group 3 | SSD: Cohort 2: Group 4 | SSD: Cohort 3: Group 5 |
|---|---|---|---|---|
| Redness: Any | 5.7 (2.7 to 10.6) | 5.1 (2.5 to 9.2) | 4.1 (1.9 to 7.7) | 4.3 (1.6 to 9.1) |
| Redness: Mild | 4.5 (1.8 to 9.0) | 3.6 (1.4 to 7.2) | 4.1 (1.9 to 7.7) | 2.1 (0.4 to 6.1) |
| Redness: Moderate | 1.3 (0.2 to 4.5) | 1.5 (0.3 to 4.4) | 0 (0.0 to 1.7) | 2.1 (0.4 to 6.1) |
| Redness: Severe | 0 (0.0 to 2.3) | 0 (0.0 to 1.9) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
| Redness: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 1.9) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
| Swelling: Any | 8.9 (5.0 to 14.5) | 4.1 (1.8 to 7.9) | 6.5 (3.6 to 10.6) | 9.2 (5.0 to 15.3) |
| Swelling: Mild | 7.0 (3.5 to 12.2) | 2.0 (0.6 to 5.1) | 5.5 (2.9 to 9.5) | 5.7 (2.5 to 10.9) |
| Swelling: Moderate | 1.3 (0.2 to 4.5) | 2.0 (0.6 to 5.1) | 0.9 (0.1 to 3.3) | 3.5 (1.2 to 8.1) |
| Swelling: Severe | 0.6 (0.0 to 3.5) | 0 (0.0 to 1.9) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
| Swelling: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 1.9) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
| Injection site pain: Any | 40.1 (32.4 to 48.2) | 74.5 (67.8 to 80.4) | 70.6 (64.1 to 76.6) | 34.5 (26.7 to 42.9) |
| Injection site pain: Mild | 29.9 (22.9 to 37.8) | 55.6 (48.4 to 62.7) | 57.8 (50.9 to 64.4) | 21.1 (14.7 to 28.8) |
| Injection site pain: Moderate | 10.2 (5.9 to 16.0) | 18.9 (13.7 to 25.1) | 12.4 (8.3 to 17.5) | 13.4 (8.3 to 20.1) |
| Injection site pain: Severe | 0 (0.0 to 2.3) | 0 (0.0 to 1.9) | 0.5 (0.0 to 2.5) | 0 (0.0 to 2.6) |
| Injection site pain | 0 (0.0 to 2.3) | 0 (0.0 to 1.9) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 3 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.
| Percentage of participants | SSD: Cohort 3: Group 5 |
|---|---|
| Redness: Any | 4.5 (1.8 to 9.1) |
| Redness: Mild | 1.3 (0.2 to 4.6) |
| Redness: Moderate | 3.2 (1.1 to 7.4) |
| Redness: Severe | 0 (0.0 to 2.4) |
| Redness: Grade 4 | 0 (0.0 to 2.4) |
| Swelling: Any | 10.4 (6.1 to 16.3) |
| Swelling: Mild | 3.2 (1.1 to 7.4) |
| Swelling: Moderate | 7.1 (3.6 to 12.4) |
| Swelling: Severe | 0 (0.0 to 2.4) |
| Swelling: Grade 4 | 0 (0.0 to 2.4) |
| Pain at the injection site: Any | 39.0 (31.2 to 47.1) |
| Pain at the injection site: Mild | 19.5 (13.5 to 26.6) |
| Pain at the injection site: Moderate | 18.8 (13.0 to 25.9) |
| Pain at the injection site: Severe | 0.6 (0.0 to 3.6) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 2.4) |
Systemic events were recorded in e-diary. Fever: oral temperature \>= 38.0 deg C, categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.
| Percentage of participants | SSD: Cohort 1: Group 1 | SSD: Cohort 1: Group 2 | SSD: Cohort 1: Group 2b | SSD: Cohort 2: Group 3 | SSD: Cohort 2: Group 4 | SSD: Cohort 3: Group 5 |
|---|---|---|---|---|---|---|
| Fever: Any | 5.8 (3.0 to 9.9) | 2.6 (0.9 to 6.0) | 5.0 (2.4 to 9.0) | 8.8 (5.9 to 12.7) | 7.2 (4.6 to 10.8) | 4.8 (2.2 to 9.0) |
| Fever: >=38.0 deg C to 38.4 deg C | 4.3 (2.0 to 8.1) | 1.6 (0.3 to 4.5) | 2.5 (0.8 to 5.7) | 4.8 (2.6 to 7.9) | 3.9 (2.1 to 6.8) | 1.1 (0.1 to 3.8) |
| Fever: >38.4 deg C to 38.9 deg C | 0.5 (0.0 to 2.7) | 0.5 (0.0 to 2.9) | 1.5 (0.3 to 4.3) | 3.4 (1.6 to 6.2) | 3.0 (1.4 to 5.5) | 2.7 (0.9 to 6.2) |
| Fever: >38.9 deg C to 40.0 deg C | 1.0 (0.1 to 3.4) | 0.5 (0.0 to 2.9) | 1.0 (0.1 to 3.5) | 0.3 (0.0 to 1.9) | 0.3 (0.0 to 1.8) | 1.1 (0.1 to 3.8) |
| Fever: >40.0 deg C | 0 (0.0 to 1.8) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 2.0) |
| Fever: Unknown | 0 (0.0 to 1.8) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 0.3 (0.0 to 1.9) | 0 (0.0 to 1.2) | 0 (0.0 to 2.0) |
| Fatigue: Any | 32.4 (26.0 to 39.2) | 26.6 (20.5 to 33.4) | 28.4 (22.2 to 35.1) | 64.6 (58.9 to 70.1) | 60.5 (54.8 to 66.1) | 39.2 (32.2 to 46.7) |
| Fatigue: Mild | 18.8 (13.8 to 24.8) | 14.6 (9.9 to 20.4) | 16.4 (11.6 to 22.3) | 26.5 (21.6 to 32.0) | 29.3 (24.2 to 34.7) | 16.7 (11.6 to 22.8) |
| Fatigue: Moderate | 12.6 (8.4 to 17.9) | 12.0 (7.7 to 17.4) | 10.9 (7.0 to 16.1) | 34.7 (29.3 to 40.4) | 28.9 (23.9 to 34.4) | 22.0 (16.3 to 28.7) |
| Fatigue: Severe | 1.0 (0.1 to 3.4) | 0 (0.0 to 1.9) | 1.0 (0.1 to 3.5) | 3.4 (1.6 to 6.2) | 2.3 (0.9 to 4.7) | 0.5 (0.0 to 3.0) |
| Fatigue: Grade 4 | 0 (0.0 to 1.8) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 2.0) |
| Headache: Any | 30.9 (24.7 to 37.7) | 27.1 (20.9 to 34.0) | 27.4 (21.3 to 34.1) | 47.6 (41.8 to 53.5) | 45.1 (39.4 to 50.8) | 27.4 (21.1 to 34.4) |
| Headache: Mild | 20.3 (15.0 to 26.4) | 15.6 (10.8 to 21.5) | 16.4 (11.6 to 22.3) | 27.2 (22.2 to 32.7) | 25.7 (20.8 to 31.0) | 10.2 (6.3 to 15.5) |
| Headache: Moderate | 10.1 (6.4 to 15.1) | 9.4 (5.7 to 14.4) | 10.4 (6.6 to 15.5) | 18.4 (14.1 to 23.3) | 17.4 (13.3 to 22.2) | 16.7 (11.6 to 22.8) |
| Headache: Severe | 0.5 (0.0 to 2.7) | 2.1 (0.6 to 5.2) | 0.5 (0.0 to 2.7) | 2.0 (0.8 to 4.4) | 2.0 (0.7 to 4.2) | 0.5 (0.0 to 3.0) |
| Headache: Grade 4 | 0 (0.0 to 1.8) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 2.0) |
| Chills: Any | 15.0 (10.4 to 20.6) | 11.5 (7.3 to 16.8) | 10.4 (6.6 to 15.5) | 31.6 (26.4 to 37.3) | 26.3 (21.5 to 31.6) | 14.0 (9.3 to 19.8) |
| Chills: Mild | 10.1 (6.4 to 15.1) | 6.8 (3.7 to 11.3) | 8.0 (4.6 to 12.6) | 13.3 (9.6 to 17.7) | 15.1 (11.3 to 19.7) | 7.0 (3.8 to 11.7) |
| Chills: Moderate | 4.3 (2.0 to 8.1) | 4.7 (2.2 to 8.7) | 2.5 (0.8 to 5.7) | 17.0 (12.9 to 21.8) | 10.2 (7.0 to 14.2) | 7.0 (3.8 to 11.7) |
| Chills: Severe | 0.5 (0.0 to 2.7) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 1.4 (0.4 to 3.4) | 1.0 (0.2 to 2.9) | 0 (0.0 to 2.0) |
| Chills: Grade 4 | 0 (0.0 to 1.8) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 2.0) |
| Vomiting: Any | 1.0 (0.1 to 3.4) | 2.1 (0.6 to 5.2) | 3.5 (1.4 to 7.0) | 2.7 (1.2 to 5.3) | 1.6 (0.5 to 3.8) | 2.2 (0.6 to 5.4) |
| Vomiting: Mild | 1.0 (0.1 to 3.4) | 1.6 (0.3 to 4.5) | 2.5 (0.8 to 5.7) | 2.4 (1.0 to 4.8) | 1.6 (0.5 to 3.8) | 0.5 (0.0 to 3.0) |
| Vomiting: Moderate | 0 (0.0 to 1.8) | 0.5 (0.0 to 2.9) | 1.0 (0.1 to 3.5) | 0.3 (0.0 to 1.9) | 0 (0.0 to 1.2) | 1.6 (0.3 to 4.6) |
| Vomiting: Severe | 0 (0.0 to 1.8) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 2.0) |
| Vomiting: Grade 4 | 0 (0.0 to 1.8) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 2.0) |
| Diarrhea: Any | 9.2 (5.6 to 14.0) | 8.3 (4.8 to 13.2) | 6.5 (3.5 to 10.8) | 8.5 (5.6 to 12.3) | 11.5 (8.2 to 15.6) | 8.1 (4.6 to 13.0) |
| Diarrhea: Mild | 8.2 (4.9 to 12.8) | 7.8 (4.4 to 12.6) | 5.0 (2.4 to 9.0) | 7.5 (4.7 to 11.1) | 9.2 (6.2 to 13.0) | 3.8 (1.5 to 7.6) |
| Diarrhea: Moderate | 1.0 (0.1 to 3.4) | 0.5 (0.0 to 2.9) | 1.5 (0.3 to 4.3) | 1.0 (0.2 to 3.0) | 2.0 (0.7 to 4.2) | 3.8 (1.5 to 7.6) |
| Diarrhea: Severe | 0 (0.0 to 1.8) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0.3 (0.0 to 1.8) | 0.5 (0.0 to 3.0) |
| Diarrhea: Grade 4 | 0 (0.0 to 1.8) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 2.0) |
| New or worsened muscle pain: Any | 15.5 (10.8 to 21.1) | 16.1 (11.2 to 22.1) | 13.9 (9.5 to 19.5) | 34.0 (28.6 to 39.7) | 28.3 (23.3 to 33.7) | 19.9 (14.4 to 26.4) |
| New or worsened muscle pain: Mild | 7.2 (4.1 to 11.7) | 6.8 (3.7 to 11.3) | 7.5 (4.2 to 12.0) | 14.6 (10.8 to 19.2) | 16.8 (12.8 to 21.5) | 6.5 (3.4 to 11.0) |
| New or worsened muscle pain: Moderate | 8.2 (4.9 to 12.8) | 9.4 (5.7 to 14.4) | 6.5 (3.5 to 10.8) | 18.7 (14.4 to 23.6) | 10.5 (7.3 to 14.5) | 12.9 (8.4 to 18.6) |
| New or worsened muscle pain: Severe | 0 (0.0 to 1.8) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 0.7 (0.1 to 2.4) | 1.0 (0.2 to 2.9) | 0.5 (0.0 to 3.0) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 1.8) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 2.0) |
| New or worsened joint pain: Any | 11.1 (7.2 to 16.2) | 13.5 (9.0 to 19.2) | 10.0 (6.2 to 14.9) | 23.5 (18.7 to 28.7) | 15.1 (11.3 to 19.7) | 12.4 (8.0 to 18.0) |
| New or worsened joint pain: Mild | 5.3 (2.7 to 9.3) | 6.8 (3.7 to 11.3) | 4.5 (2.1 to 8.3) | 10.2 (7.0 to 14.2) | 7.9 (5.1 to 11.5) | 3.8 (1.5 to 7.6) |
| New or worsened joint pain: Moderate | 5.3 (2.7 to 9.3) | 6.3 (3.3 to 10.7) | 5.5 (2.8 to 9.6) | 12.2 (8.7 to 16.5) | 7.2 (4.6 to 10.8) | 8.6 (5.0 to 13.6) |
| New or worsened joint pain: Severe | 0.5 (0.0 to 2.7) | 0.5 (0.0 to 2.9) | 0 (0.0 to 1.8) | 1.0 (0.2 to 3.0) | 0 (0.0 to 1.2) | 0 (0.0 to 2.0) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 1.8) | 0 (0.0 to 1.9) | 0 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 2.0) |
Systemic events were recorded in e-diary. Fever: oral temperature \>= 38.0 deg C, categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.
| Percentage of participants | SSD: Cohort 1: Group 2 | SSD: Cohort 2: Group 3 | SSD: Cohort 2: Group 4 | SSD: Cohort 3: Group 5 |
|---|---|---|---|---|
| Fever: Any | 1.3 (0.2 to 4.5) | 5.1 (2.5 to 9.2) | 6.0 (3.2 to 10.0) | 2.1 (0.4 to 6.1) |
| Fever:>=38.0 deg C-38.4 deg C | 0 (0.0 to 2.3) | 2.6 (0.8 to 5.9) | 3.7 (1.6 to 7.1) | 0.7 (0.0 to 3.9) |
| Fever:>38.4 deg C-38.9 deg C | 1.3 (0.2 to 4.5) | 1.0 (0.1 to 3.6) | 1.8 (0.5 to 4.7) | 1.4 (0.2 to 5.1) |
| Fever:>38.9 deg C-40.0 deg C | 0 (0.0 to 2.3) | 1.0 (0.1 to 3.6) | 0.5 (0.0 to 2.5) | 0 (0.0 to 2.6) |
| Fever:>40.0 deg C | 0 (0.0 to 2.3) | 0 (0.0 to 1.9) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
| Fever: Unknown | 0 (0.0 to 2.3) | 0.5 (0.0 to 2.8) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
| Fatigue: Any | 17.8 (12.2 to 24.7) | 60.9 (53.7 to 67.8) | 54.3 (47.5 to 61.1) | 27.0 (19.8 to 35.1) |
| Fatigue: Mild | 11.5 (6.9 to 17.5) | 27.9 (21.8 to 34.7) | 26.9 (21.2 to 33.3) | 13.5 (8.3 to 20.2) |
| Fatigue: Moderate | 5.7 (2.7 to 10.6) | 32.0 (25.5 to 39.0) | 25.1 (19.5 to 31.4) | 12.1 (7.2 to 18.6) |
| Fatigue: Severe | 0.6 (0.0 to 3.5) | 1.0 (0.1 to 3.6) | 2.3 (0.7 to 5.2) | 1.4 (0.2 to 5.0) |
| Fatigue: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 1.9) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
| Headache: Any | 24.8 (18.3 to 32.4) | 39.8 (32.9 to 47.0) | 37.3 (30.9 to 44.1) | 19.7 (13.5 to 27.2) |
| Headache: Mild | 13.4 (8.5 to 19.7) | 26.5 (20.5 to 33.3) | 18.0 (13.1 to 23.7) | 10.6 (6.0 to 16.8) |
| Headache: Moderate | 10.8 (6.4 to 16.8) | 13.3 (8.9 to 18.8) | 17.1 (12.3 to 22.7) | 9.2 (5.0 to 15.1) |
| Headache: Severe | 0.6 (0.0 to 3.5) | 0 (0.0 to 1.9) | 2.3 (0.8 to 5.3) | 0 (0.0 to 2.6) |
| Headache: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 1.9) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
| Chills: Any | 12.1 (7.4 to 18.3) | 21.8 (16.3 to 28.3) | 19.4 (14.3 to 25.2) | 7.1 (3.5 to 12.7) |
| Chills: Mild | 7.0 (3.5 to 12.2) | 10.7 (6.7 to 15.8) | 12.4 (8.4 to 17.6) | 2.1 (0.4 to 6.1) |
| Chills: Moderate | 5.1 (2.2 to 9.8) | 10.7 (6.7 to 15.8) | 6.5 (3.6 to 10.6) | 5.0 (2.0 to 10.0) |
| Chills: Severe | 0 (0.0 to 2.3) | 0.5 (0.0 to 2.8) | 0.5 (0.0 to 2.5) | 0 (0.0 to 2.6) |
| Chills: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 1.9) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
| Vomiting: Any | 2.5 (0.7 to 6.4) | 0.5 (0.0 to 2.8) | 1.8 (0.5 to 4.7) | 2.1 (0.4 to 6.1) |
| Vomiting: Mild | 1.9 (0.4 to 5.5) | 0.5 (0.0 to 2.8) | 1.8 (0.5 to 4.7) | 2.1 (0.4 to 6.1) |
| Vomiting: Moderate | 0.6 (0.0 to 3.5) | 0 (0.0 to 1.9) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
| Vomiting: Severe | 0 (0.0 to 2.3) | 0 (0.0 to 1.9) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
| Vomiting: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 1.9) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
| Diarrhea: Any | 5.1 (2.2 to 9.8) | 9.7 (5.9 to 14.7) | 6.0 (3.2 to 10.0) | 6.4 (3.0 to 11.9) |
| Diarrhea: Mild | 3.8 (1.4 to 8.1) | 8.2 (4.7 to 12.9) | 5.1 (2.6 to 8.9) | 4.3 (1.6 to 9.1) |
| Diarrhea: Moderate | 1.3 (0.2 to 4.5) | 1.5 (0.3 to 4.4) | 0.9 (0.1 to 3.3) | 2.1 (0.4 to 6.1) |
| Diarrhea: Severe | 0 (0.0 to 2.3) | 0 (0.0 to 1.9) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
| Diarrhea: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 1.9) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
| New or worsened muscle pain: Any | 10.8 (6.4 to 16.8) | 27.6 (21.4 to 34.4) | 26.7 (21.0 to 33.1) | 8.6 (4.5 to 14.5) |
| New or worsened muscle pain: Mild | 5.7 (2.7 to 10.6) | 17.9 (12.8 to 23.9) | 14.7 (10.3 to 20.2) | 4.3 (1.6 to 9.1) |
| New or worsened muscle pain: Moderate | 4.5 (1.8 to 9.0) | 9.7 (5.9 to 14.7) | 11.1 (7.2 to 16.0) | 4.3 (1.6 to 9.1) |
| New or worsened muscle pain: Severe | 0.6 (0.0 to 3.5) | 0 (0.0 to 1.9) | 0.9 (0.1 to 3.3) | 0 (0.0 to 2.6) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 1.9) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
| New or worsened joint pain: Any | 7.6 (4.0 to 13.0) | 14.3 (9.7 to 20.0) | 12.0 (8.0 to 17.1) | 5.7 (2.5 to 10.9) |
| New or worsened joint pain: Mild | 3.2 (1.0 to 7.3) | 7.1 (4.0 to 11.7) | 6.5 (3.6 to 10.6) | 2.1 (0.4 to 6.1) |
| New or worsened joint pain: Moderate | 4.5 (1.8 to 9.0) | 6.1 (3.2 to 10.5) | 5.5 (2.9 to 9.5) | 3.6 (1.2 to 8.1) |
| New or worsened joint pain: Severe | 0 (0.0 to 2.3) | 1.0 (0.1 to 3.6) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 2.3) | 0 (0.0 to 1.9) | 0 (0.0 to 1.7) | 0 (0.0 to 2.6) |
Systemic events were recorded in e-diary. Fever: oral temperature \>= 38.0 deg C and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.
| Percentage of participants | SSD: Cohort 3: Group 5 |
|---|---|
| Fever: Any | 2.6 (0.7 to 6.5) |
| Fever: >=38.0 deg C to 38.4 deg C | 0.6 (0.0 to 3.6) |
| Fever: >38.4 deg C to 38.9 deg C | 1.3 (0.2 to 4.6) |
| Fever: >38.9 deg C to 40.0 deg C | 0.6 (0.0 to 3.6) |
| Fever: >40.0 deg C | 0 (0.0 to 2.4) |
| Fatigue: Any | 22.7 (16.4 to 30.2) |
| Fatigue: Mild | 3.9 (1.4 to 8.3) |
| Fatigue: Moderate | 18.2 (12.4 to 25.2) |
| Fatigue: Severe | 0.6 (0.0 to 3.6) |
| Fatigue: Grade 4 | 0 (0.0 to 2.4) |
| Headache: Any | 25.3 (18.7 to 33.0) |
| Headache: Mild | 9.1 (5.1 to 14.8) |
| Headache: Moderate | 14.9 (9.7 to 21.6) |
| Headache: Severe | 1.3 (0.2 to 4.6) |
| Headache: Grade 4 | 0 (0.0 to 2.4) |
| Chills: Any | 9.1 (5.1 to 14.8) |
| Chills: Mild | 4.5 (1.8 to 9.1) |
| Chills: Moderate | 3.2 (1.1 to 7.4) |
| Chills: Severe | 1.3 (0.2 to 4.6) |
| Chills: Grade 4 | 0 (0.0 to 2.4) |
| Vomiting: Any | 2.6 (0.7 to 6.5) |
| Vomiting: Mild | 1.3 (0.2 to 4.6) |
| Vomiting: Moderate | 1.3 (0.2 to 4.6) |
| Vomiting: Severe | 0 (0.0 to 2.4) |
| Vomiting: Grade 4 | 0 (0.0 to 2.4) |
| Diarrhea: Any | 1.9 (0.4 to 5.6) |
| Diarrhea: Mild | 1.3 (0.2 to 4.6) |
| Diarrhea: Moderate | 0.6 (0.0 to 3.6) |
| Diarrhea: Severe | 0 (0.0 to 2.4) |
| Diarrhea: Grade 4 | 0 (0.0 to 2.4) |
| New or worsened muscle pain: Any | 14.9 (9.7 to 21.6) |
| New or worsened muscle pain: Mild | 4.5 (1.8 to 9.1) |
| New or worsened muscle pain: Moderate | 10.4 (6.1 to 16.3) |
| New or worsened muscle pain: Severe | 0 (0.0 to 2.4) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 2.4) |
| New or worsened joint pain: Any | 9.1 (5.1 to 14.8) |
| New or worsened joint pain: Mild | 3.2 (1.1 to 7.4) |
| New or worsened joint pain: Moderate | 5.2 (2.3 to 10.0) |
| New or worsened joint pain: Severe | 0.6 (0.0 to 3.6) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 2.4) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after last study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | SSD: Cohort 1: Group 1 | SSD: Cohort 1: Group 2 | SSD: Cohort 1: Group 2b |
|---|---|---|---|
| SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Last Study Vaccination: Cohort 1 | 3.2 (1.3 to 6.6) | 6.1 (3.2 to 10.4) | 2.0 (0.5 to 4.9) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after Vaccination 1 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | SSD: Cohort 2: Group 3 | SSD: Cohort 2: Group 4 |
|---|---|---|
| SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Vaccination 1: Cohort 2 | 4.1 (2.2 to 7.0) | 3.7 (1.9 to 6.4) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from Vaccination 2 up to 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | SSD: Cohort 2: Group 3 | SSD: Cohort 2: Group 4 |
|---|---|---|
| SSD: Percentage of Participants Reporting Adverse Events (AEs) From Second Study Vaccination Through 1 Month After Second Study Vaccination: Cohort 2 | 2.3 (0.8 to 5.4) | 3.8 (1.7 to 7.1) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | SSD: Cohort 3: Group 5 |
|---|---|
| SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Second Study Vaccination: Cohort 3 | 6.7 (3.7 to 10.9) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from Vaccination 3 up to 1 month after Vaccination 3 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | SSD: Cohort 3: Group 5 |
|---|---|
| SSD: Percentage of Participants Reporting Adverse Events (AEs) From Third Study Vaccination Through 1 Month After Third Study Vaccination: Cohort 3 | 0.6 (0.0 to 3.2) |
A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | SSD: Cohort 1: Group 1 | SSD: Cohort 1: Group 2 | SSD: Cohort 1: Group 2b | SSD: Cohort 3: Group 5 |
|---|---|---|---|---|
| SSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) From First Study Vaccination (Day 1) Through 6 Months After Last Study Vaccination: Cohort 1 and Cohort 3 | 0.9 (0.1 to 3.3) | 1.5 (0.3 to 4.4) | 1.0 (0.1 to 3.5) | 3.8 (1.7 to 7.4) |
A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | SSD: Cohort 2: Group 3 | SSD: Cohort 2: Group 4 |
|---|---|---|
| SSD: Percentage of Participants Reporting SAEs From First Study Vaccination (Day 1) Through 6 Months After Vaccination 1 (For Participants Who Received 1 Dose Only) and up to Vaccination 2 (For Participants Who Received 2 Doses): Cohort 2 | 1.6 (0.5 to 3.7) | 0.6 (0.1 to 2.2) |
A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | SSD: Cohort 2: Group 3 | SSD: Cohort 2: Group 4 |
|---|---|---|
| SSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) From First Study Vaccination Through 6 Months After Vaccination 2: Cohort 2 | 0.5 (0.0 to 2.6) | 1.3 (0.3 to 3.6) |
GMR was calculated based on GMT levels of SSD: Cohort 2: Group 3 and SSD: Cohort 2: Group 4 and reported in statistical analysis section below. GMT of SARS-CoV-2 Omicron strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after first study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
| Titer | SSD: Cohort 2: Group 3 | SSD: Cohort 2: Group 4 |
|---|---|---|
| SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After First Study Vaccination: Comparison Between Cohort 2 Group 3 and Group 4 | 1929.2 (1631.5 to 2281.1) | 1099.6 (932.0 to 1297.4) |
Seroresponse: achieving \>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after first study vaccination was reported in this outcome measure.
| Percentage of participants | SSD: Cohort 2: Group 3 | SSD: Cohort 2: Group 4 |
|---|---|---|
| SSD: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After First Study Vaccination: Comparison Between Cohort 2 Group 3 and Group 4 | 62.3 (53.4 to 70.7) | 39.3 (31.1 to 47.9) |
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after first study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
| Titer | SSD: Cohort 1: Group 1 | SSD: Cohort 1: Group 2b |
|---|---|---|
| SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After First Study Vaccination: Comparison Between Cohort 1 Group 1 and Group 2b | 5094.1 (4118.2 to 6301.2) | 1775.6 (1484.8 to 2123.4) |
GMR was calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after Vaccination 2 for Group 2 and 1 month after Vaccination 1 for Group 2b was reported. GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution).
| Titer | SSD: Cohort 1: Group 2 | SSD: Cohort 1: Group 2b |
|---|---|---|
| SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers: Comparison Between 1 Month After Second Study Vaccination for Cohort 1 Group 2 and 1 Month After First Study Vaccination for Cohort 1 Group 2b | 4684.3 (3937.4 to 5573.0) | 1775.6 (1484.8 to 2123.4) |
Seroresponse: achieving \>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after first study vaccination was reported in this outcome measure.
| Percentage of participants | SSD: Cohort 1: Group 1 | SSD: Cohort 1: Group 2b |
|---|---|---|
| Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After First Study Vaccination: Comparison Between Cohort 1 Group 1 and Group 2b | 88.0 (80.0 to 93.6) | 59.0 (48.7 to 68.7) |
Seroresponse: achieving \>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below LLOQ, postvaccination measure of \>= 4 × LLOQ is considered seroresponse. Exact 2-sided CI, based on Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after second study vaccination for Group 2 and 1 month after study vaccination for Group 2b was reported in this outcome measure.
| Percentage of participants | SSD: Cohort 1: Group 2 | SSD: Cohort 1: Group 2b |
|---|---|---|
| SSD: Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Vaccination 2: Comparison Between 1 Month After Vaccination 2 for Cohort 1 Group 2 and 1 Month After Vaccination 1 for Cohort 1 Group 2b | 80.0 (70.8 to 87.3) | 59.0 (48.7 to 68.7) |
GMR calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMR comparison between GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers of participants of SSD Cohort 3: Group 5 to GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers of participants of study C4591001 (NCT04368728) Phase 3 BNT162b2 single arm 18-55 years of age, at 1 month after vaccination 2 was reported. GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (student's t distribution).
| Titer | SSD: Cohort 3: Group 5 | C4591001 Study Cohort |
|---|---|---|
| SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After Second Study Vaccination: Cohort 3 | 2892.2 (2522.3 to 3316.3) | 290.6 (241.2 to 350.1) |
EIP:eligible participants received 2 doses of study drug as randomized with Dose2 received within 19-42 days after Dose1 (SSD Cohort 3:Group 5), had valid determinate immunogenicity result from blood sample collected within 28-42 days after 2nd study vaccination, had no other important protocol deviations as determined by clinician. Data of eligible participants from Study C4591001 Phase 3 BNT162b2 single arm 18-55 years was included for comparison.'N'=participants evaluable for outcome measure.
| Percentage of participants | SSD: Cohort 3: Group 5 | C4591001 Study Cohort |
|---|---|---|
| SSD: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Second Study Vaccination: Cohort 3 | 86.2 (79.7 to 91.2) | 80.8 (73.7 to 86.6) |
Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu=0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm),severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis/exfoliative dermatitis \[redness\]).Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit/hospitalization for severe pain). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions within 7 days after study vaccination and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.
| Percentage of participants | SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg | SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Redness: Any | 6.7 (0.8 to 22.1) | 0 (0.0 to 11.6) | 6.7 (0.8 to 22.1) | 8.1 (5.8 to 10.9) | 6.3 (3.1 to 11.3) | 10.9 (7.7 to 14.9) | 0 (0.0 to 16.8) | 15.0 (3.2 to 37.9) | 20.0 (5.7 to 43.7) | 10.0 (1.2 to 31.7) | 0 (0.0 to 16.8) | 10.0 (1.2 to 31.7) | 6.4 (3.9 to 9.8) | 10.4 (7.2 to 14.4) | 6.3 (3.8 to 9.7) | 10.6 (7.4 to 14.7) | 7.0 (4.4 to 10.5) | 7.4 (4.7 to 10.9) |
| Redness: Mild | 6.7 (0.8 to 22.1) | 0 (0.0 to 11.6) | 6.7 (0.8 to 22.1) | 3.8 (2.2 to 5.9) | 4.4 (1.8 to 8.9) | 6.3 (3.9 to 9.5) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 10.0 (1.2 to 31.7) | 4.0 (2.1 to 6.9) | 6.0 (3.6 to 9.4) | 3.3 (1.6 to 6.0) | 4.0 (2.1 to 6.9) | 4.3 (2.3 to 7.3) | 3.5 (1.8 to 6.2) |
| Redness: Moderate | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 4.2 (2.6 to 6.4) | 1.9 (0.4 to 5.4) | 4.4 (2.4 to 7.2) | 0 (0.0 to 16.8) | 10.0 (1.2 to 31.7) | 15.0 (3.2 to 37.9) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 2.0 (0.7 to 4.3) | 4.0 (2.1 to 6.9) | 2.7 (1.2 to 5.2) | 6.6 (4.1 to 10.1) | 2.7 (1.2 to 5.2) | 3.2 (1.5 to 5.8) |
| Redness: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0.2 (0.0 to 1.2) | 0 (0.0 to 2.3) | 0.3 (0.0 to 1.7) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0.3 (0.0 to 1.9) | 0.3 (0.0 to 1.9) | 0.3 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0.6 (0.1 to 2.3) |
| Redness: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 0.8) | 0 (0.0 to 2.3) | 0 (0.0 to 1.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) |
| Swelling: Any | 0 (0.0 to 11.6) | 6.7 (0.8 to 22.1) | 20.0 (7.7 to 38.6) | 9.6 (7.1 to 12.6) | 7.0 (3.5 to 12.1) | 11.9 (8.5 to 15.9) | 0 (0.0 to 16.8) | 10.0 (1.2 to 31.7) | 15.0 (3.2 to 37.9) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 10.0 (1.2 to 31.7) | 6.0 (3.6 to 9.4) | 13.1 (9.5 to 17.5) | 8.3 (5.4 to 12.0) | 10.0 (6.8 to 13.9) | 6.6 (4.1 to 10.1) | 5.4 (3.2 to 8.6) |
| Swelling: Mild | 0 (0.0 to 11.6) | 6.7 (0.8 to 22.1) | 13.3 (3.8 to 30.7) | 5.0 (3.2 to 7.3) | 4.4 (1.8 to 8.9) | 6.3 (3.9 to 9.5) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 10.0 (1.2 to 31.7) | 3.4 (1.6 to 6.1) | 7.7 (5.0 to 11.4) | 5.0 (2.8 to 8.1) | 4.0 (2.1 to 6.9) | 4.7 (2.6 to 7.7) | 2.9 (1.3 to 5.4) |
| Swelling: Moderate | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 6.7 (0.8 to 22.1) | 4.4 (2.7 to 6.6) | 2.5 (0.7 to 6.4) | 5.3 (3.1 to 8.4) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 10.0 (1.2 to 31.7) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 2.7 (1.2 to 5.2) | 5.4 (3.1 to 8.6) | 3.3 (1.6 to 6.0) | 5.3 (3.1 to 8.5) | 2.0 (0.7 to 4.3) | 2.2 (0.9 to 4.6) |
| Swelling: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0.2 (0.0 to 1.2) | 0 (0.0 to 2.3) | 0.3 (0.0 to 1.7) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0.7 (0.1 to 2.4) | 0 (0.0 to 1.2) | 0.3 (0.0 to 1.8) |
| Swelling: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 0.8) | 0 (0.0 to 2.3) | 0 (0.0 to 1.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) |
| Pain at the injection site: Any | 90.0 (73.5 to 97.9) | 83.3 (65.3 to 94.4) | 96.7 (82.8 to 99.9) | 82.9 (79.2 to 86.2) | 81.0 (74.0 to 86.8) | 86.3 (82.0 to 89.8) | 70.0 (45.7 to 88.1) | 70.0 (45.7 to 88.1) | 65.0 (40.8 to 84.6) | 100.0 (83.2 to 100.0) | 65.0 (40.8 to 84.6) | 85.0 (62.1 to 96.8) | 60.1 (54.3 to 65.7) | 71.1 (65.6 to 76.2) | 66.1 (60.5 to 71.4) | 70.8 (65.3 to 75.8) | 58.1 (52.3 to 63.8) | 67.9 (62.5 to 73.1) |
| Pain at the injection site: Mild | 60.0 (40.6 to 77.3) | 76.7 (57.7 to 90.1) | 33.3 (17.3 to 52.8) | 55.2 (50.6 to 59.7) | 67.7 (59.8 to 74.9) | 45.3 (39.8 to 50.9) | 55.0 (31.5 to 76.9) | 65.0 (40.8 to 84.6) | 55.0 (31.5 to 76.9) | 75.0 (50.9 to 91.3) | 60.0 (36.1 to 80.9) | 45.0 (23.1 to 68.5) | 51.7 (45.8 to 57.5) | 53.4 (47.5 to 59.1) | 52.8 (47.0 to 58.6) | 44.9 (39.1 to 50.7) | 52.8 (47.0 to 58.6) | 55.4 (49.7 to 61.0) |
| Pain at the injection site: Moderate | 30.0 (14.7 to 49.4) | 6.7 (0.8 to 22.1) | 60.0 (40.6 to 77.3) | 26.0 (22.2 to 30.2) | 13.3 (8.4 to 19.6) | 39.4 (34.0 to 45.0) | 10.0 (1.2 to 31.7) | 5.0 (0.1 to 24.9) | 10.0 (1.2 to 31.7) | 25.0 (8.7 to 49.1) | 5.0 (0.1 to 24.9) | 40.0 (19.1 to 63.9) | 8.1 (5.2 to 11.7) | 17.4 (13.3 to 22.2) | 13.3 (9.7 to 17.7) | 25.2 (20.4 to 30.6) | 5.0 (2.8 to 8.1) | 12.2 (8.8 to 16.3) |
| Pain at the injection site: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 3.3 (0.1 to 17.2) | 1.7 (0.7 to 3.3) | 0 (0.0 to 2.3) | 1.6 (0.5 to 3.6) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0.3 (0.0 to 1.9) | 0.3 (0.0 to 1.9) | 0 (0.0 to 1.2) | 0.7 (0.1 to 2.4) | 0.3 (0.0 to 1.8) | 0.3 (0.0 to 1.8) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 0.8) | 0 (0.0 to 2.3) | 0 (0.0 to 1.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) |
Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to 38.0 deg C and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C \& \>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit or hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \> 2 times in 24h, severe: required intravenous hydration and Grade 4: ER or hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit or hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.
| Percentage of participants | SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg | SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fever: >= 38.0 deg C | 13.3 (3.8 to 30.7) | 0 (0.0 to 11.6) | 10.0 (2.1 to 26.5) | 10.0 (7.5 to 13.0) | 10.8 (6.4 to 16.7) | 19.4 (15.2 to 24.1) | 5.0 (0.1 to 24.9) | 10.0 (1.2 to 31.7) | 10.0 (1.2 to 31.7) | 5.0 (0.1 to 24.9) | 20.0 (5.7 to 43.7) | 20.0 (5.7 to 43.7) | 3.7 (1.9 to 6.5) | 7.4 (4.7 to 11.0) | 8.3 (5.4 to 12.0) | 9.0 (6.0 to 12.8) | 5.0 (2.8 to 8.1) | 7.7 (5.0 to 11.2) |
| Fever: >= 38.0 deg C to 38.4 deg C | 3.3 (0.1 to 17.2) | 0 (0.0 to 11.6) | 10.0 (2.1 to 26.5) | 4.2 (2.6 to 6.4) | 6.3 (3.1 to 11.3) | 6.9 (4.4 to 10.2) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 15.0 (3.2 to 37.9) | 5.0 (0.1 to 24.9) | 2.0 (0.7 to 4.3) | 3.7 (1.9 to 6.5) | 3.7 (1.8 to 6.4) | 4.7 (2.6 to 7.7) | 3.7 (1.8 to 6.4) | 5.4 (3.2 to 8.6) |
| Fever: >38.4 deg C to 38.9 deg C | 10.0 (2.1 to 26.5) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 3.8 (2.2 to 5.9) | 3.8 (1.4 to 8.1) | 8.1 (5.4 to 11.7) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 10.0 (1.2 to 31.7) | 1.7 (0.5 to 3.9) | 3.7 (1.9 to 6.5) | 3.7 (1.8 to 6.4) | 2.7 (1.2 to 5.2) | 0 (0.0 to 1.2) | 1.6 (0.5 to 3.7) |
| Fever: >38.9 deg C to 40.0 deg C | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 2.1 (1.0 to 3.8) | 0.6 (0.0 to 3.5) | 4.4 (2.4 to 7.2) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 1.0 (0.2 to 2.9) | 1.3 (0.4 to 3.4) | 1.3 (0.4 to 3.4) | 0.6 (0.1 to 2.3) |
| Fever: >40 deg C | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 0.8) | 0 (0.0 to 2.3) | 0 (0.0 to 1.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0.3 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) |
| Fatigue: Any | 66.7 (47.2 to 82.7) | 63.3 (43.9 to 80.1) | 70.0 (50.6 to 85.3) | 73.8 (69.6 to 77.6) | 68.4 (60.5 to 75.5) | 77.5 (72.5 to 82.0) | 45.0 (23.1 to 68.5) | 55.0 (31.5 to 76.9) | 45.0 (23.1 to 68.5) | 65.0 (40.8 to 84.6) | 40.0 (19.1 to 63.9) | 70.0 (45.7 to 88.1) | 45.3 (39.6 to 51.1) | 52.3 (46.5 to 58.1) | 52.5 (46.7 to 58.3) | 58.8 (53.0 to 64.4) | 49.2 (43.4 to 55.0) | 57.4 (51.7 to 62.9) |
| Fatigue: Mild | 20.0 (7.7 to 38.6) | 26.7 (12.3 to 45.9) | 23.3 (9.9 to 42.3) | 25.2 (21.4 to 29.3) | 32.3 (25.1 to 40.2) | 25.9 (21.2 to 31.1) | 30.0 (11.9 to 54.3) | 15.0 (3.2 to 37.9) | 10.0 (1.2 to 31.7) | 35.0 (15.4 to 59.2) | 15.0 (3.2 to 37.9) | 45.0 (23.1 to 68.5) | 23.5 (18.8 to 28.7) | 22.5 (17.9 to 27.7) | 20.3 (15.9 to 25.3) | 24.6 (19.8 to 29.9) | 29.2 (24.2 to 34.7) | 27.2 (22.4 to 32.5) |
| Fatigue: Moderate | 43.3 (25.5 to 62.6) | 33.3 (17.3 to 52.8) | 40.0 (22.7 to 59.4) | 44.0 (39.5 to 48.5) | 34.8 (27.4 to 42.8) | 46.9 (41.3 to 52.5) | 10.0 (1.2 to 31.7) | 40.0 (19.1 to 63.9) | 35.0 (15.4 to 59.2) | 30.0 (11.9 to 54.3) | 25.0 (8.7 to 49.1) | 25.0 (8.7 to 49.1) | 21.5 (17.0 to 26.6) | 26.8 (21.9 to 32.3) | 29.6 (24.5 to 35.1) | 30.6 (25.4 to 36.1) | 18.3 (14.1 to 23.1) | 28.2 (23.3 to 33.5) |
| Fatigue: Severe | 3.3 (0.1 to 17.2) | 3.3 (0.1 to 17.2) | 6.7 (0.8 to 22.1) | 4.6 (2.9 to 6.9) | 1.3 (0.2 to 4.5) | 4.7 (2.6 to 7.6) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0.3 (0.0 to 1.9) | 3.0 (1.4 to 5.7) | 2.7 (1.2 to 5.2) | 3.7 (1.8 to 6.4) | 1.7 (0.5 to 3.8) | 1.9 (0.7 to 4.1) |
| Fatigue: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 0.8) | 0 (0.0 to 2.3) | 0 (0.0 to 1.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) |
| Headache: Any | 46.7 (28.3 to 65.7) | 30.0 (14.7 to 49.4) | 60.0 (40.6 to 77.3) | 53.5 (49.0 to 58.1) | 50.0 (42.0 to 58.0) | 57.5 (51.9 to 63.0) | 20.0 (5.7 to 43.7) | 30.0 (11.9 to 54.3) | 35.0 (15.4 to 59.2) | 15.0 (3.2 to 37.9) | 30.0 (11.9 to 54.3) | 50.0 (27.2 to 72.8) | 26.5 (21.6 to 31.9) | 38.9 (33.4 to 44.7) | 36.5 (31.1 to 42.3) | 36.5 (31.1 to 42.3) | 33.6 (28.2 to 39.2) | 36.5 (31.2 to 42.1) |
| Headache: Mild | 40.0 (22.7 to 59.4) | 23.3 (9.9 to 42.3) | 26.7 (12.3 to 45.9) | 27.7 (23.7 to 31.9) | 29.1 (22.2 to 36.9) | 27.5 (22.7 to 32.7) | 10.0 (1.2 to 31.7) | 30.0 (11.9 to 54.3) | 30.0 (11.9 to 54.3) | 10.0 (1.2 to 31.7) | 20.0 (5.7 to 43.7) | 25.0 (8.7 to 49.1) | 15.8 (11.8 to 20.4) | 23.5 (18.8 to 28.7) | 22.3 (17.7 to 27.4) | 20.6 (16.2 to 25.6) | 23.6 (18.9 to 28.8) | 24.4 (19.7 to 29.5) |
| Headache: Moderate | 6.7 (0.8 to 22.1) | 6.7 (0.8 to 22.1) | 30.0 (14.7 to 49.4) | 24.2 (20.4 to 28.3) | 19.0 (13.2 to 26.0) | 27.2 (22.4 to 32.4) | 10.0 (1.2 to 31.7) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 10.0 (1.2 to 31.7) | 25.0 (8.7 to 49.1) | 10.4 (7.2 to 14.4) | 14.4 (10.6 to 18.9) | 13.3 (9.7 to 17.7) | 14.6 (10.8 to 19.1) | 9.6 (6.5 to 13.5) | 10.9 (7.7 to 14.9) |
| Headache: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 3.3 (0.1 to 17.2) | 1.7 (0.7 to 3.3) | 1.9 (0.4 to 5.4) | 2.8 (1.3 to 5.3) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0.3 (0.0 to 1.9) | 1.0 (0.2 to 2.9) | 1.0 (0.2 to 2.9) | 1.3 (0.4 to 3.4) | 0.3 (0.0 to 1.8) | 1.3 (0.4 to 3.2) |
| Headache: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 0.8) | 0 (0.0 to 2.3) | 0 (0.0 to 1.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) |
| Chills: Any | 23.3 (9.9 to 42.3) | 23.3 (9.9 to 42.3) | 40.0 (22.7 to 59.4) | 35.6 (31.3 to 40.1) | 27.8 (21.0 to 35.5) | 38.4 (33.1 to 44.0) | 5.0 (0.1 to 24.9) | 20.0 (5.7 to 43.7) | 15.0 (3.2 to 37.9) | 35.0 (15.4 to 59.2) | 25.0 (8.7 to 49.1) | 30.0 (11.9 to 54.3) | 16.4 (12.4 to 21.1) | 24.2 (19.4 to 29.4) | 25.6 (20.7 to 30.9) | 25.6 (20.7 to 30.9) | 13.0 (9.4 to 17.3) | 23.7 (19.1 to 28.8) |
| Chills: Mild | 13.3 (3.8 to 30.7) | 13.3 (3.8 to 30.7) | 13.3 (3.8 to 30.7) | 20.4 (16.9 to 24.3) | 15.8 (10.5 to 22.5) | 18.8 (14.6 to 23.5) | 0 (0.0 to 16.8) | 15.0 (3.2 to 37.9) | 5.0 (0.1 to 24.9) | 30.0 (11.9 to 54.3) | 5.0 (0.1 to 24.9) | 10.0 (1.2 to 31.7) | 10.7 (7.5 to 14.8) | 13.1 (9.5 to 17.5) | 13.0 (9.4 to 17.3) | 11.3 (8.0 to 15.4) | 8.3 (5.4 to 12.0) | 13.5 (9.9 to 17.8) |
| Chills: Moderate | 10.0 (2.1 to 26.5) | 10.0 (2.1 to 26.5) | 20.0 (7.7 to 38.6) | 14.6 (11.5 to 18.1) | 11.4 (6.9 to 17.4) | 17.8 (13.8 to 22.5) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 10.0 (1.2 to 31.7) | 5.0 (0.1 to 24.9) | 20.0 (5.7 to 43.7) | 15.0 (3.2 to 37.9) | 5.7 (3.4 to 9.0) | 10.4 (7.2 to 14.4) | 12.0 (8.5 to 16.2) | 12.0 (8.5 to 16.2) | 4.7 (2.6 to 7.7) | 10.3 (7.1 to 14.2) |
| Chills: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 6.7 (0.8 to 22.1) | 0.6 (0.1 to 1.8) | 0.6 (0.0 to 3.5) | 1.9 (0.7 to 4.0) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 0 (0.0 to 1.2) | 0.7 (0.1 to 2.4) | 0.7 (0.1 to 2.4) | 2.3 (0.9 to 4.7) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) |
| Chills: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 0.8) | 0 (0.0 to 2.3) | 0 (0.0 to 1.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) |
| Vomiting: Any | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 3.1 (1.8 to 5.1) | 0.6 (0.0 to 3.5) | 3.8 (2.0 to 6.5) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 1.3 (0.4 to 3.4) | 1.7 (0.5 to 3.9) | 3.0 (1.4 to 5.6) | 2.7 (1.2 to 5.2) | 1.7 (0.5 to 3.8) | 1.3 (0.4 to 3.2) |
| Vomiting: Mild | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 2.7 (1.4 to 4.6) | 0.6 (0.0 to 3.5) | 3.4 (1.7 to 6.1) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 0.7 (0.1 to 2.4) | 1.3 (0.4 to 3.4) | 2.3 (0.9 to 4.7) | 2.3 (0.9 to 4.7) | 1.7 (0.5 to 3.8) | 1.3 (0.4 to 3.2) |
| Vomiting: Moderate | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0.4 (0.1 to 1.5) | 0 (0.0 to 2.3) | 0.3 (0.0 to 1.7) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0.7 (0.1 to 2.4) | 0.3 (0.0 to 1.9) | 0.7 (0.1 to 2.4) | 0.3 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) |
| Vomiting: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 0.8) | 0 (0.0 to 2.3) | 0 (0.0 to 1.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) |
| Vomiting: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 0.8) | 0 (0.0 to 2.3) | 0 (0.0 to 1.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) |
| Diarrhea: Any | 20.0 (7.7 to 38.6) | 3.3 (0.1 to 17.2) | 13.3 (3.8 to 30.7) | 12.7 (9.9 to 16.0) | 10.8 (6.4 to 16.7) | 12.2 (8.8 to 16.3) | 15.0 (3.2 to 37.9) | 15.0 (3.2 to 37.9) | 15.0 (3.2 to 37.9) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 4.4 (2.3 to 7.3) | 5.7 (3.4 to 9.0) | 8.0 (5.2 to 11.6) | 10.3 (7.1 to 14.3) | 9.0 (6.0 to 12.8) | 6.4 (4.0 to 9.7) |
| Diarrhea: Mild | 16.7 (5.6 to 34.7) | 3.3 (0.1 to 17.2) | 13.3 (3.8 to 30.7) | 9.6 (7.1 to 12.6) | 9.5 (5.4 to 15.2) | 10.0 (6.9 to 13.8) | 10.0 (1.2 to 31.7) | 10.0 (1.2 to 31.7) | 10.0 (1.2 to 31.7) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 3.4 (1.6 to 6.1) | 3.7 (1.9 to 6.5) | 6.6 (4.1 to 10.1) | 9.0 (6.0 to 12.8) | 6.0 (3.6 to 9.3) | 5.8 (3.5 to 9.0) |
| Diarrhea: Moderate | 3.3 (0.1 to 17.2) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 3.1 (1.8 to 5.1) | 1.3 (0.2 to 4.5) | 2.2 (0.9 to 4.5) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 1.0 (0.2 to 2.9) | 2.0 (0.7 to 4.3) | 0.7 (0.1 to 2.4) | 1.3 (0.4 to 3.4) | 1.7 (0.5 to 3.8) | 0.6 (0.1 to 2.3) |
| Diarrhea: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 0.8) | 0 (0.0 to 2.3) | 0 (0.0 to 1.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0.7 (0.1 to 2.4) | 0 (0.0 to 1.2) | 1.3 (0.4 to 3.4) | 0 (0.0 to 1.2) |
| Diarrhea: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 0.8) | 0 (0.0 to 2.3) | 0 (0.0 to 1.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) |
| New or worsened muscle pain: Any | 30.0 (14.7 to 49.4) | 30.0 (14.7 to 49.4) | 46.7 (28.3 to 65.7) | 39.8 (35.4 to 44.3) | 36.7 (29.2 to 44.7) | 42.2 (36.7 to 47.8) | 25.0 (8.7 to 49.1) | 20.0 (5.7 to 43.7) | 25.0 (8.7 to 49.1) | 35.0 (15.4 to 59.2) | 20.0 (5.7 to 43.7) | 35.0 (15.4 to 59.2) | 19.8 (15.4 to 24.8) | 25.5 (20.7 to 30.8) | 23.9 (19.2 to 29.1) | 30.6 (25.4 to 36.1) | 22.3 (17.7 to 27.4) | 27.2 (22.4 to 32.5) |
| New or worsened muscle pain: Mild | 6.7 (0.8 to 22.1) | 10.0 (2.1 to 26.5) | 23.3 (9.9 to 42.3) | 18.3 (15.0 to 22.1) | 20.3 (14.3 to 27.4) | 17.8 (13.8 to 22.5) | 10.0 (1.2 to 31.7) | 15.0 (3.2 to 37.9) | 10.0 (1.2 to 31.7) | 25.0 (8.7 to 49.1) | 5.0 (0.1 to 24.9) | 25.0 (8.7 to 49.1) | 11.7 (8.3 to 16.0) | 10.1 (6.9 to 14.1) | 11.6 (8.2 to 15.8) | 12.6 (9.1 to 16.9) | 13.3 (9.7 to 17.7) | 14.1 (10.4 to 18.5) |
| New or worsened muscle pain: Moderate | 23.3 (9.9 to 42.3) | 20.0 (7.7 to 38.6) | 23.3 (9.9 to 42.3) | 21.3 (17.7 to 25.2) | 15.8 (10.5 to 22.5) | 22.2 (17.8 to 27.1) | 15.0 (3.2 to 37.9) | 5.0 (0.1 to 24.9) | 15.0 (3.2 to 37.9) | 10.0 (1.2 to 31.7) | 15.0 (3.2 to 37.9) | 10.0 (1.2 to 31.7) | 8.1 (5.2 to 11.7) | 14.4 (10.6 to 18.9) | 12.0 (8.5 to 16.2) | 15.9 (12.0 to 20.6) | 9.0 (6.0 to 12.8) | 12.8 (9.3 to 17.0) |
| New or worsened muscle pain: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0.2 (0.0 to 1.2) | 0.6 (0.0 to 3.5) | 2.2 (0.9 to 4.5) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 1.2) | 1.0 (0.2 to 2.9) | 0.3 (0.0 to 1.8) | 2.0 (0.7 to 4.3) | 0 (0.0 to 1.2) | 0.3 (0.0 to 1.8) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 0.8) | 0 (0.0 to 2.3) | 0 (0.0 to 1.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) |
| New or worsened joint pain: Any | 20.0 (7.7 to 38.6) | 16.7 (5.6 to 34.7) | 23.3 (9.9 to 42.3) | 25.4 (21.6 to 29.6) | 20.9 (14.8 to 28.1) | 24.1 (19.5 to 29.1) | 20.0 (5.7 to 43.7) | 25.0 (8.7 to 49.1) | 15.0 (3.2 to 37.9) | 20.0 (5.7 to 43.7) | 15.0 (3.2 to 37.9) | 35.0 (15.4 to 59.2) | 9.1 (6.1 to 12.9) | 16.1 (12.1 to 20.8) | 16.6 (12.6 to 21.3) | 19.6 (15.3 to 24.5) | 11.3 (8.0 to 15.4) | 18.6 (14.4 to 23.4) |
| New or worsened joint pain: Mild | 10.0 (2.1 to 26.5) | 13.3 (3.8 to 30.7) | 10.0 (2.1 to 26.5) | 12.5 (9.7 to 15.8) | 10.1 (5.9 to 15.9) | 9.1 (6.2 to 12.8) | 10.0 (1.2 to 31.7) | 15.0 (3.2 to 37.9) | 5.0 (0.1 to 24.9) | 20.0 (5.7 to 43.7) | 5.0 (0.1 to 24.9) | 15.0 (3.2 to 37.9) | 5.4 (3.1 to 8.6) | 9.7 (6.6 to 13.7) | 9.3 (6.3 to 13.2) | 8.3 (5.4 to 12.0) | 7.6 (4.9 to 11.2) | 10.3 (7.1 to 14.2) |
| New or worsened joint pain: Moderate | 10.0 (2.1 to 26.5) | 3.3 (0.1 to 17.2) | 13.3 (3.8 to 30.7) | 12.5 (9.7 to 15.8) | 10.8 (6.4 to 16.7) | 14.1 (10.4 to 18.4) | 10.0 (1.2 to 31.7) | 10.0 (1.2 to 31.7) | 10.0 (1.2 to 31.7) | 0 (0.0 to 16.8) | 10.0 (1.2 to 31.7) | 20.0 (5.7 to 43.7) | 3.7 (1.9 to 6.5) | 6.0 (3.6 to 9.4) | 7.3 (4.6 to 10.9) | 11.0 (7.7 to 15.1) | 3.7 (1.8 to 6.4) | 8.0 (5.3 to 11.6) |
| New or worsened joint pain: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0.4 (0.1 to 1.5) | 0 (0.0 to 2.3) | 0.9 (0.2 to 2.7) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 1.2) | 0.3 (0.0 to 1.9) | 0 (0.0 to 1.2) | 0.3 (0.0 to 1.8) | 0 (0.0 to 1.2) | 0.3 (0.0 to 1.8) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 0.8) | 0 (0.0 to 2.3) | 0 (0.0 to 1.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) | 0 (0.0 to 1.2) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg | SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SSE: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination | 13.3 (3.8 to 30.7) | 6.7 (0.8 to 22.1) | 13.3 (3.8 to 30.7) | 7.7 (5.5 to 10.4) | 6.3 (3.1 to 11.3) | 9.3 (6.4 to 13.1) | 10.0 (1.2 to 31.7) | 0 (0.0 to 16.8) | 15.0 (3.2 to 37.9) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 5.9 (3.5 to 9.2) | 6.6 (4.1 to 10.0) | 8.5 (5.6 to 12.2) | 3.6 (1.8 to 6.3) | 6.2 (3.8 to 9.6) | 10.4 (7.3 to 14.4) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg | SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SSE: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Month After Study Vaccination | 0 (0.0 to 0.0) | 0 (0.0 to 0.0) | 0 (0.0 to 0.0) | 0.6 (0.1 to 1.8) | 1.3 (0.2 to 4.5) | 0.9 (0.2 to 2.7) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 2.0 (0.7 to 4.2) | 0.7 (0.1 to 2.4) | 3.9 (2.0 to 6.7) | 1.3 (0.4 to 3.3) | 1.3 (0.4 to 3.3) | 1.9 (0.7 to 4.1) |
Percentage of participants with elevated troponin I levels before study vaccination were reported in this outcome measure.
| Percentage of participants | SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg | SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg |
|---|---|---|---|
| SSE: Percentage of Participants With Elevated Troponin I Levels Before the Study Vaccination- 18 to 55 Years of Age | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) |
Percentage of participants with elevated troponin I levels before study vaccination were reported in this outcome measure.
| Percentage of participants | SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg | SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg |
|---|---|---|---|
| SSE: Percentage of Participants With Elevated Troponin I Levels 3 Days After Study Vaccination- 18 to 55 Years of Age | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) |
GMR calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
| Titer | SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg |
|---|---|---|---|---|---|
| SSE: Geometric Mean Ratio (GMR) Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After Study Vaccination | 455.8 (365.9 to 567.6) | 1014.5 (825.6 to 1246.7) | 1435.2 (1208.1 to 1704.8) | 711.0 (588.3 to 859.2) | 900.1 (726.3 to 1115.6) |
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below lower limit of quantification (LLOQ), postvaccination measure of \>= 4 × LLOQ is considered seroresponse. Exact 2-sided CI, based on Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.
| Percentage of participants | SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg |
|---|---|---|---|---|---|
| SSE: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Study Vaccination | 57.0 (48.7 to 65.1) | 76.7 (69.4 to 82.9) | 86.1 (79.9 to 91.0) | 71.6 (64.2 to 78.3) | 67.9 (60.1 to 75.0) |
GMT of SARS-CoV-2 Omicron BA.1 strain neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
| Titer | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Geometric Mean Titer (GMTs) of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers Before Vaccination | 41.7 (22.4 to 77.4) | 33.2 (17.6 to 62.6) | 32.0 (17.0 to 60.1) | 36.8 (17.5 to 77.1) | 78.8 (29.3 to 211.6) | 21.5 (14.2 to 32.7) |
Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (necrosis \[swelling\] or necrosis/exfoliative dermatitis \[redness\]). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after study vaccination and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.
| Percentage of participants | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| Redness: Any | 19.0 (5.4 to 41.9) | 21.1 (6.1 to 45.6) | 23.8 (8.2 to 47.2) | 20.0 (5.7 to 43.7) | 10.0 (1.2 to 31.7) | 28.6 (11.3 to 52.2) |
| Redness: Mild | 4.8 (0.1 to 23.8) | 10.5 (1.3 to 33.1) | 14.3 (3.0 to 36.3) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 23.8 (8.2 to 47.2) |
| Redness: Moderate | 14.3 (3.0 to 36.3) | 10.5 (1.3 to 33.1) | 9.5 (1.2 to 30.4) | 10.0 (1.2 to 31.7) | 5.0 (0.1 to 24.9) | 4.8 (0.1 to 23.8) |
| Redness: Severe | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Redness: Grade 4 | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Swelling: Any | 14.3 (3.0 to 36.3) | 15.8 (3.4 to 39.6) | 14.3 (3.0 to 36.3) | 15.0 (3.2 to 37.9) | 15.0 (3.2 to 37.9) | 28.6 (11.3 to 52.2) |
| Swelling: Mild | 4.8 (0.1 to 23.8) | 5.3 (0.1 to 26.0) | 4.8 (0.1 to 23.8) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 23.8 (8.2 to 47.2) |
| Swelling: Moderate | 9.5 (1.2 to 30.4) | 10.5 (1.3 to 33.1) | 9.5 (1.2 to 30.4) | 10.0 (1.2 to 31.7) | 10.0 (1.2 to 31.7) | 4.8 (0.1 to 23.8) |
| Swelling: Severe | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Swelling: Grade 4 | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Pain at the injection site: Any | 71.4 (47.8 to 88.7) | 94.7 (74.0 to 99.9) | 90.5 (69.6 to 98.8) | 80.0 (56.3 to 94.3) | 75.0 (50.9 to 91.3) | 90.5 (69.6 to 98.8) |
| Pain at the injection site: Mild | 52.4 (29.8 to 74.3) | 52.6 (28.9 to 75.6) | 66.7 (43.0 to 85.4) | 45.0 (23.1 to 68.5) | 55.0 (31.5 to 76.9) | 57.1 (34.0 to 78.2) |
| Pain at the injection site: Moderate | 19.0 (5.4 to 41.9) | 36.8 (16.3 to 61.6) | 19.0 (5.4 to 41.9) | 35.0 (15.4 to 59.2) | 20.0 (5.7 to 43.7) | 33.3 (14.6 to 57.0) |
| Pain at the injection site: Severe | 0 (0.0 to 16.1) | 5.3 (0.1 to 26.0) | 4.8 (0.1 to 23.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to 38.0 deg C and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C \& \>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit or hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \> 2 times in 24h, severe: required intravenous hydration and Grade 4: ER or hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit or hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.
| Percentage of participants | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| Fever: >= 38.0 deg C | 9.5 (1.2 to 30.4) | 10.5 (1.3 to 33.1) | 9.5 (1.2 to 30.4) | 10.0 (1.2 to 31.7) | 5.0 (0.1 to 24.9) | 4.8 (0.1 to 23.8) |
| Fever: >= 38.0 deg C to 38.4 deg C | 9.5 (1.2 to 30.4) | 5.3 (0.1 to 26.0) | 4.8 (0.1 to 23.8) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 4.8 (0.1 to 23.8) |
| Fever: >38.4 deg C to 38.9 deg C | 0 (0.0 to 16.1) | 5.3 (0.1 to 26.0) | 0 (0.0 to 16.1) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.1) |
| Fever: >38.9 deg C to 40.0 deg C | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 4.8 (0.1 to 23.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Fever: >40.0 deg C | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Fatigue: Any | 47.6 (25.7 to 70.2) | 36.8 (16.3 to 61.6) | 42.9 (21.8 to 66.0) | 55.0 (31.5 to 76.9) | 50.0 (27.2 to 72.8) | 57.1 (34.0 to 78.2) |
| Fatigue: Mild | 9.5 (1.2 to 30.4) | 10.5 (1.3 to 33.1) | 9.5 (1.2 to 30.4) | 10.0 (1.2 to 31.7) | 5.0 (0.1 to 24.9) | 23.8 (8.5 to 47.2) |
| Fatigue: Moderate | 23.8 (8.2 to 47.2) | 21.1 (6.1 to 45.6) | 28.6 (11.3 to 52.2) | 35.0 (15.4 to 59.2) | 40.0 (19.1 to 63.9) | 33.3 (14.6 to 57.0) |
| Fatigue: Severe | 14.3 (3.0 to 36.3) | 5.3 (0.1 to 26.0) | 4.8 (0.1 to 23.8) | 10.0 (1.2 to 31.7) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.1) |
| Fatigue: Grade 4 | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Headache: Any | 28.6 (11.3 to 52.2) | 26.3 (9.1 to 51.2) | 23.8 (8.2 to 47.2) | 55.0 (31.5 to 76.9) | 35.0 (15.4 to 59.2) | 38.1 (18.1 to 61.6) |
| Headache: Mild | 19.0 (5.4 to 41.9) | 15.8 (3.4 to 39.6) | 4.8 (0.1 to 23.8) | 15.0 (3.2 to 37.9) | 20.0 (5.7 to 43.7) | 19.0 (5.4 to 41.9) |
| Headache: Moderate | 9.5 (1.2 to 30.4) | 10.5 (1.3 to 33.1) | 14.3 (3.0 to 36.3) | 40.0 (19.1 to 63.9) | 15.0 (3.2 to 37.9) | 19.0 (5.4 to 41.9) |
| Headache: Severe | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 4.8 (0.1 to 23.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.7) | 0 (0.0 to 16.1) |
| Headache: Grade 4 | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Chills: Any | 14.3 (3.0 to 36.3) | 15.8 (3.4 to 39.6) | 23.8 (8.2 to 47.2) | 25.0 (8.7 to 49.1) | 5.0 (0.1 to 24.9) | 14.3 (3.0 to 36.3) |
| Chills: Mild | 4.8 (0.1 to 23.8) | 10.5 (1.3 to 33.1) | 14.3 (3.0 to 36.3) | 10.0 (1.2 to 31.7) | 0 (0.0 to 16.8) | 9.5 (1.2 to 30.4) |
| Chills: Moderate | 9.5 (1.2 to 30.4) | 5.3 (0.1 to 26.0) | 4.8 (0.1 to 23.8) | 5.0 (0.1 to 24.9) | 5.0 (0.1 to 24.9) | 4.8 (0.1 to 23.8) |
| Chills: Severe | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 4.8 (0.1 to 23.8) | 10.0 (1.2 to 31.7) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Chills: Grade 4 | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Vomiting: Any | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Vomiting: Mild | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Vomiting: Moderate | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Vomiting: Severe | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Vomiting: Grade 4 | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Diarrhea: Any | 14.3 (3.0 to 36.3) | 5.3 (0.1 to 26.0) | 9.5 (1.2 to 30.4) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Diarrhea: Mild | 9.5 (1.2 to 30.4) | 5.3 (0.1 to 26.0) | 4.8 (0.1 to 23.8) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Diarrhea: Moderate | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 4.8 (0.1 to 23.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Diarrhea: Severe | 4.8 (0.1 to 23.8) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| Diarrhea: Grade 4 | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| New or worsened muscle pain: Any | 19.0 (5.4 to 41.9) | 42.1 (20.3 to 66.5) | 23.8 (8.2 to 47.2) | 30.0 (11.9 to 54.3) | 25.0 (8.7 to 49.1) | 28.6 (11.3 to 52.2) |
| New or worsened muscle pain: Mild | 4.8 (0.1 to 23.8) | 10.5 (1.3 to 33.1) | 14.3 (3.0 to 36.3) | 10.0 (1.2 to 31.9) | 15.0 (3.2 to 37.9) | 23.8 (8.2 to 47.2) |
| New or worsened muscle pain: Moderate | 14.3 (3.0 to 36.3) | 31.6 (12.6 to 56.6) | 4.8 (0.1 to 23.8) | 20.0 (5.7 to 43.7) | 10.0 (1.2 to 31.7) | 4.8 (0.1 to 23.8) |
| New or worsened muscle pain: Severe | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 4.8 (0.1 to 23.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| New or worsened joint pain: Any | 14.3 (3.0 to 36.3) | 15.8 (3.4 to 39.6) | 14.3 (3.0 to 36.3) | 20.0 (5.7 to 43.7) | 10.0 (1.2 to 31.7) | 9.5 (1.2 to 30.4) |
| New or worsened joint pain: Mild | 4.8 (0.1 to 23.8) | 10.5 (1.3 to 33.1) | 9.5 (1.2 to 30.4) | 10.0 (1.2 to 31.7) | 10.0 (1.2 to 31.7) | 4.8 (0.1 to 23.8) |
| New or worsened joint pain: Moderate | 9.5 (1.2 to 30.4) | 5.3 (0.1 to 26.0) | 4.8 (0.1 to 23.8) | 10.0 (1.2 to 31.7) | 0 (0.0 to 16.8) | 4.8 (0.1 to 23.8) |
| New or worsened joint pain: Severe | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 16.1) | 0 (0.0 to 17.6) | 0 (0.0 to 16.1) | 0 (0.0 to 16.8) | 0 (0.0 to 16.8) | 0 (0.0 to 16.1) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination | 0 (0.0 to 16.1) | 10.5 (1.3 to 33.1) | 9.5 (1.2 to 30.4) | 5.0 (0.1 to 24.9) | 10.0 (1.2 to 31.7) | 0 (0.0 to 16.1) |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Months After Study Vaccination | 0 (0.0 to 16.1) | 5.3 (0.1 to 26.0) | 4.8 (0.1 to 23.8) | 0 (0.0 to 16.8) | 5.0 (0.1 to 24.9) | 0 (0.0 to 16.1) |
GMT of SARS-CoV-2 reference-strain-neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
| Titer | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMTs of SARS-CoV-2 Reference-Strain-Neutralizing Titers Before Vaccination | 541.1 (345.1 to 848.3) | 382.4 (176.3 to 829.3) | 437.5 (244.0 to 784.2) | 315.2 (188.0 to 528.4) | 803.4 (347.8 to 1855.8) | 256.0 (135.1 to 485.0) |
GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
| Titer | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMTs of SARS-CoV-2 Omicron BA.4/BA.5 Strain Neutralizing Titers Before Vaccination | 27.1 (16.8 to 43.7) | 18.0 (12.1 to 26.7) | 20.2 (12.6 to 32.3) | 23.4 (13.9 to 39.4) | 42.2 (19.6 to 91.1) | 15.0 (11.8 to 19.1) |
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Titer | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Geometric Mean Ratio (GMR) Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Day 7 | 146.1 (102.5 to 208.2) | 101.6 (48.6 to 212.6) | 217.1 (97.8 to 481.9) | 315.2 (164.6 to 603.5) | 337.8 (133.8 to 852.7) | 222.9 (125.7 to 395.1) |
GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Titer | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Day 7 | 1917.2 (1153.8 to 3185.7) | 1241.4 (624.3 to 2468.6) | 1472.3 (855.4 to 2534.0) | 1499.2 (838.6 to 2680.4) | 2702.4 (1419.7 to 5143.8) | 1845.8 (1087.4 to 3133.1) |
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Titer | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain Neutralizing Titers at Day 7 | 75.5 (52.7 to 108.0) | 56.6 (32.1 to 99.8) | 73.0 (38.7 to 137.9) | 76.1 (46.0 to 125.9) | 123.6 (63.8 to 239.5) | 70.7 (48.5 to 103.0) |
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Titer | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 1 | 420.0 (252.2 to 699.5) | 188.1 (88.9 to 398.2) | 699.4 (398.9 to 1226.4) | 675.6 (343.2 to 1329.8) | 1024.0 (509.4 to 2058.3) | 477.7 (236.0 to 967.1) |
GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Titer | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 1 | 4674.1 (3112.1 to 7020.2) | 2048.4 (1007.8 to 4163.7) | 3327.0 (1867.6 to 5926.9) | 3565.8 (1992.1 to 6382.7) | 5404.7 (3359.8 to 8694.1) | 2521.4 (1388.9 to 4577.4) |
GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Titer | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 1 | 157.6 (94.0 to 264.2) | 85.7 (52.5 to 139.8) | 151.0 (72.6 to 314.1) | 230.7 (140.0 to 379.2) | 284.0 (134.7 to 599.1) | 147.0 (86.3 to 250.4) |
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Titer | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 3 | 247.3 (119.7 to 510.7) | 118.5 (54.6 to 257.1) | 461.4 (203.8 to 1044.7) | 711.0 (388.8 to 1300.1) | 512.0 (246.9 to 1061.6) | 285.6 (132.8 to 614.1) |
GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Titer | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 3 | 2896.3 (1738.8 to 4824.3) | 1290.2 (675.2 to 2465.3) | 2610.3 (1265.9 to 5382.4) | 2949.6 (1550.2 to 5612.3) | 2610.3 (1506.5 to 4522.8) | 1474.8 (815.0 to 2668.9) |
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Titer | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 3 | 222.9 (123.3 to 402.7) | 132.8 (63.7 to 276.7) | 322.5 (147.6 to 704.6) | 458.9 (206.8 to 1018.6) | 296.2 (143.2 to 612.6) | 141.3 (86.4 to 231.1) |
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Titer | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 6 | 239.6 (98.8 to 581.4) | 229.5 (68.7 to 766.4) | 1058.4 (490.3 to 2284.6) | 1722.2 (844.3 to 3512.9) | 588.1 (280.3 to 1234.2) | 284.0 (131.8 to 612.4) |
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Titer | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 6 | 1424.5 (667.9 to 3037.9) | 1371.0 (508.5 to 3696.4) | 2756.4 (1328.0 to 5721.4) | 3956.5 (2256.3 to 6937.8) | 2702.4 (1457.6 to 5010.0) | 1097.5 (555.3 to 2169.1) |
GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Titer | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 6 | 203.2 (85.5 to 483.1) | 265.5 (75.9 to 928.9) | 645.1 (281.1 to 1480.5) | 1305.2 (601.1 to 2834.1) | 430.5 (204.7 to 905.4) | 187.4 (80.5 to 436.3) |
GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
| Fold rise | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Geometric Mean Fold-Rise (GMFR) of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination | 3.5 (2.1 to 5.8) | 2.9 (1.6 to 5.4) | 6.8 (4.3 to 10.7) | 8.6 (5.1 to 14.3) | 4.3 (2.0 to 9.1) | 9.8 (6.9 to 14.0) |
GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
| Fold rise | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination | 3.5 (2.5 to 5.0) | 3.1 (1.8 to 5.2) | 3.4 (2.2 to 5.1) | 4.8 (3.0 to 7.5) | 3.4 (1.4 to 8.1) | 6.3 (3.9 to 10.2) |
GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
| Fold rise | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination | 2.8 (2.1 to 3.7) | 2.8 (1.8 to 4.4) | 3.6 (2.5 to 5.2) | 3.2 (2.2 to 4.8) | 2.9 (1.9 to 4.4) | 4.7 (3.4 to 6.5) |
GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
| Fold rise | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination | 10.1 (5.5 to 18.4) | 5.4 (2.6 to 11.4) | 20.4 (11.8 to 35.3) | 18.4 (9.5 to 35.6) | 13.0 (6.7 to 25.1) | 21.1 (11.5 to 38.8) |
GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
| Fold rise | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination | 8.6 (5.5 to 13.6) | 5.0 (2.5 to 10.0) | 7.2 (4.7 to 10.9) | 11.3 (6.2 to 20.8) | 6.7 (3.7 to 12.1) | 8.6 (4.1 to 17.8) |
GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
| Fold rise | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination | 5.9 (3.8 to 9.1) | 4.7 (3.1 to 7.1) | 7.5 (4.6 to 12.3) | 9.8 (7.3 to 13.3) | 6.7 (3.5 to 13.0) | 9.5 (6.0 to 15.2) |
GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
| Fold rise | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination | 5.9 (2.7 to 12.8) | 3.3 (1.4 to 7.5) | 13.5 (6.0 to 30.0) | 17.9 (8.7 to 36.5) | 6.5 (3.2 to 13.1) | 12.0 (6.4 to 22.3) |
GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
| Fold rise | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination | 5.0 (2.9 to 8.5) | 3.2 (1.6 to 6.3) | 5.6 (2.6 to 11.9) | 8.6 (4.3 to 17.2) | 3.2 (1.8 to 5.8) | 4.5 (2.4 to 8.2) |
GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
| Fold rise | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination | 8.6 (4.3 to 16.9) | 7.4 (3.7 to 14.9) | 16.0 (7.5 to 34.0) | 18.5 (9.2 to 37.3) | 7.2 (4.1 to 12.7) | 9.4 (5.9 to 15.2) |
GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
| Fold rise | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination | 5.8 (2.2 to 15.0) | 6.9 (1.6 to 30.4) | 33.1 (13.7 to 79.6) | 46.9 (17.6 to 124.7) | 7.5 (2.4 to 22.8) | 12.6 (5.8 to 27.3) |
GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
| Fold rise | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination | 2.6 (1.1 to 6.1) | 3.6 (1.0 to 12.7) | 6.3 (2.6 to 15.2) | 12.6 (6.0 to 26.1) | 3.4 (1.3 to 8.9) | 3.9 (1.8 to 8.2) |
GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
| Fold rise | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination | 7.5 (2.8 to 20.2) | 16.6 (4.1 to 66.8) | 32.0 (12.7 to 80.7) | 55.7 (22.2 to 140.0) | 10.2 (3.7 to 28.0) | 13.0 (5.4 to 31.4) |
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.
| Percentage of participants | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Day 7 | 52.4 (29.8 to 74.3) | 44.4 (21.5 to 69.2) | 71.4 (47.8 to 88.7) | 85.0 (62.1 to 96.8) | 55.0 (31.5 to 76.9) | 90.0 (68.3 to 98.8) |
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.
| Percentage of participants | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Day 7 | 52.4 (29.8 to 74.3) | 55.6 (30.8 to 78.5) | 61.9 (38.4 to 81.9) | 80.0 (56.3 to 94.3) | 55.0 (31.5 to 76.9) | 80.0 (56.3 to 94.3) |
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.
| Percentage of participants | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Day 7 | 33.3 (14.6 to 57.0) | 43.8 (19.8 to 70.1) | 42.9 (21.8 to 66.0) | 40.0 (19.1 to 63.9) | 40.0 (19.1 to 63.9) | 61.9 (38.4 to 81.9) |
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.
| Percentage of participants | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 1 | 85.7 (63.7 to 97.0) | 61.1 (35.7 to 82.7) | 90.0 (68.3 to 98.8) | 85.0 (62.1 to 96.8) | 90.0 (68.3 to 98.8) | 85.0 (62.1 to 96.8) |
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.
| Percentage of participants | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 1 | 81.0 (58.1 to 94.6) | 61.1 (35.7 to 82.7) | 85.0 (62.1 to 96.8) | 85.0 (62.1 to 96.8) | 70.0 (45.7 to 88.1) | 75.0 (50.9 to 91.3) |
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.
| Percentage of participants | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 1 | 75.0 (50.9 to 91.3) | 61.1 (35.7 to 82.7) | 66.7 (43.0 to 85.4) | 95.0 (75.1 to 99.9) | 80.0 (56.3 to 94.3) | 85.0 (62.1 to 96.8) |
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.
| Percentage of participants | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 3 | 65.0 (40.8 to 84.6) | 50.0 (26.0 to 74.0) | 75.0 (50.9 to 91.3) | 84.2 (60.4 to 96.6) | 70.0 (45.7 to 88.1) | 89.5 (66.9 to 98.7) |
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.
| Percentage of participants | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 3 | 65.0 (40.8 to 84.6) | 55.6 (30.8 to 78.5) | 65.0 (40.8 to 84.6) | 78.9 (54.4 to 93.9) | 55.0 (31.5 to 76.9) | 63.2 (38.4 to 83.7) |
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.
| Percentage of participants | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 3 | 75.0 (50.9 to 91.3) | 61.1 (35.7 to 82.7) | 85.7 (63.7 to 97.0) | 84.2 (60.4 to 96.6) | 63.2 (38.4 to 83.7) | 85.7 (63.7 to 97.0) |
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.
| Percentage of participants | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 6 | 42.9 (21.8 to 66.0) | 47.4 (24.4 to 71.1) | 85.7 (63.7 to 97.0) | 90.0 (68.3 to 98.8) | 65.0 (40.8 to 84.6) | 85.0 (62.1 to 96.8) |
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.
| Percentage of participants | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 6 | 42.9 (21.8 to 66.0) | 42.1 (20.3 to 66.5) | 61.9 (38.4 to 81.9) | 85.0 (62.1 to 96.8) | 55.0 (31.5 to 76.9) | 50.0 (27.2 to 72.8) |
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.
| Percentage of participants | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg |
|---|---|---|---|---|---|---|
| SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 6 | 52.4 (29.8 to 74.3) | 50.0 (26.0 to 74.0) | 85.7 (63.7 to 97.0) | 90.0 (68.3 to 98.8) | 70.0 (45.7 to 88.1) | 75.0 (50.9 to 91.3) |
Occurrence (number of cases) of first severe COVID-19 infection based on FDA definition after booster dose without past SARS-CoV-2 infection is reported. FDA definition: confirmed COVID-19 and presence of at least 1 of the following: 1) clinical signs at rest indicative of severe systemic illness (respiratory rate greater than or equal to \[\>=\]30 breaths per minute, heart rate \>= 125 beats per minute, oxygen saturation less than or equal to \[\<=\]93% on room air at sea level, or Horovitz quotient \<300 mmHg); 2) respiratory failure (needing high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation); 3) evidence of shock (systolic blood pressure \[BP\] \<90 mmHg, diastolic BP \<60 mmHg, or requiring vasopressors); 4) significant acute renal, hepatic, or neurologic dysfunction; 5) admission to an intensive care unit; 6) death.
| Number of 1st severe Covid19cases/1000PY | SSA: BNT162b2 30 mcg: Blinded and Open Label Period | SSA: Placebo: Blinded Period |
|---|---|---|
| SSA: Occurrence of First Severe COVID-19 Infection (FDA Definition) Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection: Evaluable Efficacy Population | 0 | 2.103 |
Occurrence (number of cases) of first severe COVID-19 infection based on FDA definition after booster dose with and without past SARS-CoV-2 infection is reported. FDA definition: confirmed COVID-19 and presence of at least 1 of the following: 1) clinical signs at rest indicative of severe systemic illness (respiratory rate \>= 30 breaths per minute, heart rate \>= 125 beats per minute, oxygen saturation \<= 93% on room air at sea level, or Horovitz quotient \<300 mm Hg); 2) respiratory failure (defined as needing high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation); 3) evidence of shock (systolic BP \<90 mm Hg, diastolic BP \<60 mm Hg, or requiring vasopressors); 4) significant acute renal, hepatic, or neurologic dysfunction; 5) admission to an intensive care unit; 6) death.
| Number of 1st severe Covid19cases/1000PY | SSA: BNT162b2 30 mcg: Blinded and Open Label Period | SSA: Placebo: Blinded Period |
|---|---|---|
| SSA: Occurrence of First Severe COVID-19 Infection (FDA Definition) Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection: Evaluable Efficacy Population | 0 | 1.978 |
Occurrence (number of cases) of first severe COVID-19 infection based on CDC definition after booster dose without past SARS-CoV-2 infection is reported. CDC definition: confirmed COVID-19 and presence of at least 1 of the following: 1) hospitalization; 2) admission to an intensive care unit; 3) intubation or mechanical ventilation; 4) death.
| Number of 1st severe Covid19cases/1000PY | SSA: BNT162b2 30 mcg: Blinded and Open Label Period | SSA: Placebo: Blinded Period |
|---|---|---|
| SSA: Occurrence of First Severe COVID-19 Infection (CDC Definition) Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection | 0 | 0 |
Occurrence (number of cases) of first severe COVID-19 infection based on CDC definition after booster dose with and without past SARS-CoV-2 infection is reported. CDC definition: confirmed COVID-19 AND presence of at least 1 of the following: 1) hospitalization; 2) admission to an intensive care unit; 3) intubation or mechanical ventilation; 4) death.
| Number of 1st severe Covid19cases/1000PY | SSA: BNT162b2 30 mcg: Blinded and Open Label Period | SSA: Placebo: Blinded Period |
|---|---|---|
| SSA: Occurrence of First Severe COVID-19 Infection (CDC Definition) Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection | 0 | 0 |
GMT of SARS-CoV-2 reference-strain neutralizing titers at baseline and 7 days after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
| Titer | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg |
|---|---|---|
| Baseline | 1846.7 (1232.1 to 2767.9) | 2230.4 (1451.8 to 3426.7) |
| Day 7 | 15193.4 (12335.9 to 18712.8) | 22689.7 (18949.8 to 27167.7) |
GMT of SARS-CoV-2 Omicron BA.1- neutralizing titers at baseline and 7 days after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
| Titer | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg |
|---|---|---|
| Baseline | 68.2 (39.1 to 119.1) | 131.1 (68.7 to 250.7) |
| Day 7 | 1356.4 (970.1 to 1896.4) | 2655.7 (2046.7 to 3445.9) |
GMFR of SARS-CoV-2 reference-strain-neutralizing titers from baseline (before the booster dose) to 7 days after the booster dose was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
| Fold rise | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg |
|---|---|---|
| SSC: GMFRs of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Baseline to 7 Days After the Booster Dose | 8.2 (5.9 to 11.5) | 10.2 (6.8 to 15.2) |
GMFR of SARS-CoV-2 Omicron BA.1-strain-neutralizing titers from baseline (before the booster dose) to 7 days after the booster dose was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).
| Fold rise | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg |
|---|---|---|
| SSC: GMFRs of SARS-CoV-2 Omicron BA.1-Neutralizing Titers From Baseline to 7 Days After the Booster Dose | 19.7 (12.3 to 31.6) | 20.2 (11.7 to 35.0) |
Seroresponse was defined as achieving \>= 4-fold rise from before booster dose. If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse to reference strain at 7 days after the booster dose was reported in this outcome measure.
| Percentage of participants | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg |
|---|---|---|
| SSC: Percentages of Participants With Seroresponse to Reference Strain at 7 Days After the Booster Dose | 71.2 (56.9 to 82.9) | 68.1 (52.9 to 80.9) |
Seroresponse was defined as achieving \>= 4-fold rise from before booster dose. If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse to Omicron BA.1 strain at 7 days after the booster dose was reported in this outcome measure.
| Percentage of participants | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg |
|---|---|---|
| SSC: Percentages of Participants With Seroresponse to Omicron BA.1 at 7 Days After the Booster Dose | 77.6 (63.4 to 88.2) | 74.5 (59.7 to 86.1) |
GMR based on GMT of SARS-CoV-2 reference strain neutralizing titers was calculated and reported in statistical analysis section. GMT of SARS-CoV-2 Reference strain-neutralizing titers at 1 month after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).
| Titer | SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg |
|---|---|---|---|
| SSE: GMR Based on Geometric Mean Titers of SARS-CoV-2 Reference Strain Neutralizing Titers at 1 Month After the Study Vaccination- >55 Years of Age | 5998.1 (5223.6 to 6887.4) | 5933.2 (5188.2 to 6785.2) | 7816.9 (6820.7 to 8958.6) |
Collected over Death/SAEs: 6 months after last dose (or 1 month after each dose for SSB, or 6 months after BNT162b2 for SSA original placebo). Non-SAEs: 1 month after each booster dose (or after Dose 2 for SSD naïve group, or after BNT162b2 for SSA original placebo). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SSA: BNT162b2 30 mcg- Blinded and Open Label Period | 5/5,080 (0.1%) | 73/5,080 (1.4%) | 1,201/5,080 (23.6%) |
| SSA: Placebo: Blinded Period | 2/5,041 (0%) | 42/5,041 (0.8%) | 202/5,041 (4%) |
| SSA: Original Placebo/BNT162b2 (30 mcg)- Open Label Period | 5/4,429 (0.1%) | 45/4,429 (1%) | 771/4,429 (17.4%) |
| SSB: BNT162b2 | 0/1,453 (0%) | 2/1,453 (0.1%) | 1,180/1,453 (81.2%) |
| SSB: Placebo | 0/1,463 (0%) | 2/1,463 (0.1%) | 615/1,463 (42%) |
| SSF: BNT162b2 30 mcg | 0/21 (0%) | 0/21 (0%) | 17/21 (81%) |
| SSF: BNT162b2 60 mcg | 0/19 (0%) | 1/19 (5.3%) | 19/19 (100%) |
| SSF: BNT162b2 OMI 30 mcg | 0/21 (0%) | 1/21 (4.8%) | 20/21 (95.2%) |
| SSF: BNT162b2 OMI 60 mcg | 0/20 (0%) | 0/20 (0%) | 18/20 (90%) |
| SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | 0/20 (0%) | 1/20 (5%) | 18/20 (90%) |
| SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg | 0/21 (0%) | 0/21 (0%) | 20/21 (95.2%) |
| SSC: BNT162b2 10 mcg | 0/75 (0%) | 0/75 (0%) | 49/75 (65.3%) |
| SSC: BNT162b2 30 mcg | 0/65 (0%) | 1/65 (1.5%) | 57/65 (87.7%) |
| SSD: Cohort 1: Group 1 | 0/216 (0%) | 2/216 (0.9%) | 124/216 (57.4%) |
| SSD: Cohort 1: Group 2a | 2/197 (1%) | 3/197 (1.5%) | 131/197 (66.5%) |
| SSD: Cohort 1: Group 2b | 1/204 (0.5%) | 2/204 (1%) | 109/204 (53.4%) |
| SSD: Cohort 2: Group 3a | 1/315 (0.3%) | 5/315 (1.6%) | 260/315 (82.5%) |
| SSD: Cohort 2: Group 3 b | 0/213 (0%) | 1/213 (0.5%) | 167/213 (78.4%) |
| SSD: Cohort 2: Group 4a | 0/323 (0%) | 2/323 (0.6%) | 270/323 (83.6%) |
| SSD: Cohort 2: Group 4b | 0/238 (0%) | 3/238 (1.3%) | 175/238 (73.5%) |
| SSD: Cohort 3: Group 5a | 1/210 (0.5%) | 7/210 (3.3%) | 135/210 (64.3%) |
| SSD: Cohort 3: Group 5b | 1/172 (0.6%) | 1/172 (0.6%) | 69/172 (40.1%) |
| SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg | 0/30 (0%) | 0/30 (0%) | 29/30 (96.7%) |
| SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | 0/30 (0%) | 0/30 (0%) | 27/30 (90%) |
| SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | 0/30 (0%) | 0/30 (0%) | 29/30 (96.7%) |
| SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg | 0/482 (0%) | 3/482 (0.6%) | 431/482 (89.4%) |
| SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | 0/159 (0%) | 2/159 (1.3%) | 143/159 (89.9%) |
| SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | 0/321 (0%) | 3/321 (0.9%) | 297/321 (92.5%) |
| SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg | 0/20 (0%) | 1/20 (5%) | 15/20 (75%) |
| SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg | 0/20 (0%) | 0/20 (0%) | 15/20 (75%) |
| SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg | 0/20 (0%) | 0/20 (0%) | 15/20 (75%) |
| SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg | 0/20 (0%) | 0/20 (0%) | 20/20 (100%) |
| SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | 0/20 (0%) | 0/20 (0%) | 16/20 (80%) |
| SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | 1/20 (5%) | 1/20 (5%) | 17/20 (85%) |
| SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg | 0/305 (0%) | 6/305 (2%) | 220/305 (72.1%) |
| SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg | 0/302 (0%) | 2/302 (0.7%) | 243/302 (80.5%) |
| SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg | 1/307 (0.3%) | 12/307 (3.9%) | 241/307 (78.5%) |
| SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg | 1/307 (0.3%) | 4/307 (1.3%) | 248/307 (80.8%) |
| SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | 0/308 (0%) | 4/308 (1.3%) | 226/308 (73.4%) |
| SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | 1/313 (0.3%) | 6/313 (1.9%) | 247/313 (78.9%) |
| Event | SSA: BNT162b2 30 mcg- Blinded and Open Label Period | SSA: Placebo: Blinded Period | SSA: Original Placebo/BNT162b2 (30 mcg)- Open Label Period | SSB: BNT162b2 | SSB: Placebo | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg | SSD: Cohort 1: Group 1 | SSD: Cohort 1: Group 2a | SSD: Cohort 1: Group 2b | SSD: Cohort 2: Group 3a | SSD: Cohort 2: Group 3 b | SSD: Cohort 2: Group 4a | SSD: Cohort 2: Group 4b | SSD: Cohort 3: Group 5a | SSD: Cohort 3: Group 5b | SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg | SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/5080 | 1/5041 | 0/4429 | 0/1453 | 0/1463 | 0/21 | 1/19 | 0/21 | 0/20 | 0/20 | 0/21 | 0/75 | 0/65 | 0/216 | 0/197 | 0/204 | 0/315 | 0/213 | 0/323 | 0/238 | 0/210 | 0/172 | 0/30 | 0/30 | 0/30 | 0/482 | 0/159 | 0/321 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/305 | 0/302 | 0/307 | 0/307 | 0/308 | 0/313 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/5080 | 1/5041 | 1/4429 | 0/1453 | 0/1463 | 0/21 | 0/19 | 0/21 | 0/20 | 1/20 | 0/21 | 0/75 | 0/65 | 0/216 | 0/197 | 0/204 | 0/315 | 0/213 | 0/323 | 0/238 | 0/210 | 0/172 | 0/30 | 0/30 | 0/30 | 0/482 | 0/159 | 0/321 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/305 | 0/302 | 0/307 | 0/307 | 0/308 | 0/313 |
| Brain neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/5080 | 0/5041 | 0/4429 | 0/1453 | 0/1463 | 0/21 | 0/19 | 0/21 | 0/20 | 0/20 | 0/21 | 0/75 | 0/65 | 0/216 | 0/197 | 0/204 | 0/315 | 0/213 | 0/323 | 0/238 | 0/210 | 0/172 | 0/30 | 0/30 | 0/30 | 0/482 | 0/159 | 0/321 | 1/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/305 | 0/302 | 0/307 | 0/307 | 0/308 | 0/313 |
| Cardiopulmonary failureCardiac disorders | 0/5080 | 0/5041 | 0/4429 | 0/1453 | 0/1463 | 0/21 | 0/19 | 0/21 | 0/20 | 0/20 | 0/21 | 0/75 | 0/65 | 0/216 | 0/197 | 0/204 | 0/315 | 0/213 | 0/323 | 0/238 | 0/210 | 0/172 | 0/30 | 0/30 | 0/30 | 0/482 | 0/159 | 0/321 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 1/20 | 0/305 | 0/302 | 0/307 | 0/307 | 0/308 | 0/313 |
| VertigoEar and labyrinth disorders | 0/5080 | 0/5041 | 0/4429 | 0/1453 | 0/1463 | 0/21 | 0/19 | 1/21 | 0/20 | 0/20 | 0/21 | 0/75 | 0/65 | 0/216 | 0/197 | 0/204 | 0/315 | 0/213 | 0/323 | 0/238 | 0/210 | 0/172 | 0/30 | 0/30 | 0/30 | 0/482 | 0/159 | 0/321 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/305 | 0/302 | 0/307 | 0/307 | 0/308 | 0/313 |
| ConstipationGastrointestinal disorders | 0/5080 | 0/5041 | 0/4429 | 0/1453 | 0/1463 | 0/21 | 0/19 | 0/21 | 0/20 | 0/20 | 0/21 | 0/75 | 1/65 | 0/216 | 0/197 | 0/204 | 0/315 | 0/213 | 0/323 | 0/238 | 0/210 | 0/172 | 0/30 | 0/30 | 0/30 | 0/482 | 0/159 | 0/321 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/305 | 0/302 | 0/307 | 0/307 | 0/308 | 0/313 |
| Dilated cardiomyopathyCardiac disorders | 0/5080 | 0/5041 | 0/4429 | 0/1453 | 0/1463 | 0/21 | 0/19 | 0/21 | 0/20 | 0/20 | 0/21 | 0/75 | 0/65 | 0/216 | 2/197 | 0/204 | 0/315 | 0/213 | 0/323 | 0/238 | 0/210 | 0/172 | 0/30 | 0/30 | 0/30 | 0/482 | 0/159 | 0/321 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/305 | 0/302 | 0/307 | 0/307 | 0/308 | 0/313 |
| Atrial fibrillationCardiac disorders | 3/5080 | 0/5041 | 2/4429 | 0/1453 | 0/1463 | 0/21 | 0/19 | 0/21 | 0/20 | 0/20 | 0/21 | 0/75 | 0/65 | 0/216 | 0/197 | 0/204 | 0/315 | 0/213 | 0/323 | 0/238 | 0/210 | 0/172 | 0/30 | 0/30 | 0/30 | 0/482 | 0/159 | 0/321 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/305 | 0/302 | 0/307 | 0/307 | 0/308 | 3/313 |
| PneumoniaInfections and infestations | 0/5080 | 1/5041 | 1/4429 | 0/1453 | 0/1463 | 0/21 | 0/19 | 0/21 | 0/20 | 0/20 | 0/21 | 0/75 | 0/65 | 0/216 | 0/197 | 0/204 | 0/315 | 0/213 | 0/323 | 0/238 | 0/210 | 0/172 | 0/30 | 0/30 | 0/30 | 0/482 | 0/159 | 0/321 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 2/305 | 0/302 | 0/307 | 0/307 | 0/308 | 0/313 |
| CellulitisInfections and infestations | 1/5080 | 0/5041 | 1/4429 | 1/1453 | 0/1463 | 0/21 | 0/19 | 0/21 | 0/20 | 0/20 | 0/21 | 0/75 | 0/65 | 0/216 | 0/197 | 0/204 | 0/315 | 0/213 | 0/323 | 0/238 | 0/210 | 0/172 | 0/30 | 0/30 | 0/30 | 0/482 | 1/159 | 0/321 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/305 | 0/302 | 0/307 | 0/307 | 0/308 | 0/313 |
| Event | SSA: BNT162b2 30 mcg- Blinded and Open Label Period | SSA: Placebo: Blinded Period | SSA: Original Placebo/BNT162b2 (30 mcg)- Open Label Period | SSB: BNT162b2 | SSB: Placebo | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg | SSD: Cohort 1: Group 1 | SSD: Cohort 1: Group 2a | SSD: Cohort 1: Group 2b | SSD: Cohort 2: Group 3a | SSD: Cohort 2: Group 3 b | SSD: Cohort 2: Group 4a | SSD: Cohort 2: Group 4b | SSD: Cohort 3: Group 5a | SSD: Cohort 3: Group 5b | SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg | SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site pain (PAIN)General disorders | 0/5080 | 0/5041 | 0/4429 | 1038/1453 | 163/1463 | 15/21 | 18/19 | 19/21 | 16/20 | 15/20 | 19/21 | 42/75 | 50/65 | 96/216 | 110/197 | 85/204 | 229/315 | 145/213 | 239/323 | 153/238 | 109/210 | 60/172 | 27/30 | 25/30 | 29/30 | 398/482 | 128/159 | 276/321 | 14/20 | 14/20 | 13/20 | 20/20 | 13/20 | 17/20 | 179/305 | 212/302 | 199/307 | 214/307 | 177/308 | 208/313 |
| Fatigue (FATIGUE)General disorders | 0/5080 | 0/5041 | 0/4429 | 723/1453 | 356/1463 | 10/21 | 7/19 | 9/21 | 11/20 | 10/20 | 12/21 | 37/75 | 35/65 | 67/216 | 61/197 | 57/204 | 189/315 | 119/213 | 184/323 | 117/238 | 87/210 | 35/172 | 20/30 | 19/30 | 21/30 | 354/482 | 108/159 | 248/321 | 9/20 | 11/20 | 9/20 | 13/20 | 8/20 | 14/20 | 135/305 | 156/302 | 158/307 | 177/307 | 147/308 | 177/313 |
| Headache (HEADACHE)Nervous system disorders | 0/5080 | 0/5041 | 0/4429 | 585/1453 | 332/1463 | 6/21 | 5/19 | 5/21 | 11/20 | 7/20 | 8/21 | 31/75 | 34/65 | 64/216 | 70/197 | 55/204 | 140/315 | 78/213 | 137/323 | 81/238 | 67/210 | 39/172 | 14/30 | 9/30 | 18/30 | 257/482 | 79/159 | 184/321 | 4/20 | 6/20 | 7/20 | 3/20 | 6/20 | 10/20 | 79/305 | 116/302 | 110/307 | 110/307 | 99/308 | 114/313 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 0/5080 | 0/5041 | 0/4429 | 402/1453 | 88/1463 | 4/21 | 8/19 | 5/21 | 6/20 | 5/20 | 6/21 | 0/75 | 0/65 | 32/216 | 41/197 | 28/204 | 99/315 | 51/213 | 86/323 | 58/238 | 45/210 | 23/172 | 9/30 | 9/30 | 14/30 | 191/482 | 58/159 | 135/321 | 5/20 | 4/20 | 5/20 | 7/20 | 4/20 | 7/20 | 59/305 | 76/302 | 72/307 | 92/307 | 70/308 | 82/313 |
| Chills (CHILLS)General disorders | 0/5080 | 0/5041 | 0/4429 | 278/1453 | 69/1463 | 3/21 | 3/19 | 5/21 | 5/20 | 1/20 | 3/21 | 10/75 | 15/65 | 31/216 | 35/197 | 21/204 | 93/315 | 39/213 | 80/323 | 41/238 | 32/210 | 14/172 | 7/30 | 7/30 | 12/30 | 171/482 | 44/159 | 123/321 | 1/20 | 4/20 | 3/20 | 7/20 | 5/20 | 6/20 | 49/305 | 72/302 | 77/307 | 78/307 | 38/308 | 74/313 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 0/5080 | 0/5041 | 0/4429 | 178/1453 | 55/1463 | 3/21 | 3/19 | 3/21 | 4/20 | 2/20 | 2/21 | 0/75 | 0/65 | 23/216 | 33/197 | 20/204 | 69/315 | 28/213 | 46/323 | 26/238 | 29/210 | 14/172 | 6/30 | 5/30 | 7/30 | 122/482 | 33/159 | 77/321 | 4/20 | 5/20 | 3/20 | 4/20 | 3/20 | 7/20 | 27/305 | 48/302 | 50/307 | 59/307 | 34/308 | 57/313 |
| Injection site erythema (REDNESS)General disorders | 0/5080 | 0/5041 | 0/4429 | 74/1453 | 9/1463 | 4/21 | 4/19 | 5/21 | 4/20 | 2/20 | 6/21 | 1/75 | 4/65 | 7/216 | 18/197 | 5/204 | 21/315 | 10/213 | 13/323 | 9/238 | 14/210 | 7/172 | 2/30 | 0/30 | 2/30 | 39/482 | 10/159 | 35/321 | 0/20 | 3/20 | 4/20 | 2/20 | 0/20 | 2/20 | 19/305 | 31/302 | 19/307 | 33/307 | 22/308 | 22/313 |
| Injection site swelling (SWELLING)General disorders | 0/5080 | 0/5041 | 0/4429 | 86/1453 | 7/1463 | 3/21 | 3/19 | 3/21 | 3/20 | 3/20 | 6/21 | 2/75 | 6/65 | 17/216 | 23/197 | 11/204 | 25/315 | 8/213 | 27/323 | 14/238 | 27/210 | 16/172 | 0/30 | 2/30 | 6/30 | 46/482 | 11/159 | 38/321 | 0/20 | 2/20 | 3/20 | 1/20 | 1/20 | 2/20 | 18/305 | 39/302 | 25/307 | 31/307 | 20/308 | 17/313 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 0/5080 | 0/5041 | 0/4429 | 109/1453 | 77/1463 | 3/21 | 1/19 | 2/21 | 1/20 | 0/20 | 0/21 | 3/75 | 6/65 | 19/216 | 20/197 | 13/204 | 25/315 | 18/213 | 35/323 | 13/238 | 20/210 | 3/172 | 6/30 | 1/30 | 4/30 | 61/482 | 17/159 | 39/321 | 3/20 | 3/20 | 3/20 | 0/20 | 1/20 | 1/20 | 13/305 | 17/302 | 24/307 | 31/307 | 26/308 | 21/313 |
| Pyrexia (FEVER)General disorders | 0/5080 | 0/5041 | 0/4429 | 74/1453 | 17/1463 | 2/21 | 2/19 | 2/21 | 2/20 | 1/20 | 1/21 | 3/75 | 4/65 | 12/216 | 7/197 | 10/204 | 25/315 | 9/213 | 22/323 | 13/238 | 11/210 | 4/172 | 4/30 | 0/30 | 3/30 | 48/482 | 17/159 | 62/321 | 1/20 | 2/20 | 2/20 | 1/20 | 4/20 | 4/20 | 11/305 | 22/302 | 25/307 | 27/307 | 15/308 | 24/313 |
Safety population included all randomized participants who received at least 1 dose of the study intervention.
| Age, Customized(Participants) | SSA: BNT162b2 30 mcg: Blinded and Open Label Period | SSA: Placebo: Blinded Period | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg | SSD: Cohort 1: Group 1 | SSD: Cohort 1: Group 2 | SSD: Cohort 1: Group 2b | SSD: Cohort 2: Group 3 | SSD: Cohort 2: Group 4 | SSD: Cohort 3: Group 5 | SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg | SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adolescents (12-17 years) | 46 | 44 | 233 | 228 | 75 | 65 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 691 |
| Adults (18-64 years) | 3859 | 3811 | 520 | 504 | 0 | 0 | 216 | 197 | 204 | 315 | 323 | 210 | 30 | 30 | 30 | 482 | 159 | 321 | 6 | 5 | 5 | 7 | 5 | 9 | 126 | 105 | 121 | 123 | 112 | 109 | 6 | 7 | 6 | 8 | 9 | 9 | 11989 |
| From 65-84 years | 1166 | 1174 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 15 | 15 | 13 | 15 | 10 | 176 | 196 | 186 | 183 | 194 | 199 | 15 | 12 | 15 | 12 | 11 | 12 | 3633 |
| 85 years and over | 9 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 0 | 1 | 2 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 34 |
| Sex: Female, Male(Participants) | SSA: BNT162b2 30 mcg: Blinded and Open Label Period | SSA: Placebo: Blinded Period | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg | SSD: Cohort 1: Group 1 | SSD: Cohort 1: Group 2 | SSD: Cohort 1: Group 2b | SSD: Cohort 2: Group 3 | SSD: Cohort 2: Group 4 | SSD: Cohort 3: Group 5 | SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg | SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2624 | 2526 | 434 | 447 | 37 | 33 | 137 | 119 | 121 | 152 | 156 | 106 | 14 | 17 | 15 | 269 | 89 | 180 | 8 | 9 | 14 | 12 | 7 | 11 | 160 | 157 | 153 | 154 | 144 | 162 | 9 | 9 | 13 | 10 | 8 | 12 | 8528 |
| Male | 2456 | 2515 | 319 | 285 | 38 | 32 | 79 | 78 | 83 | 163 | 167 | 104 | 16 | 13 | 15 | 213 | 70 | 141 | 12 | 11 | 6 | 8 | 13 | 9 | 145 | 145 | 154 | 153 | 164 | 151 | 12 | 10 | 8 | 10 | 12 | 9 | 7819 |
| Race/Ethnicity, Customized(Participants) | SSA: BNT162b2 30 mcg: Blinded and Open Label Period | SSA: Placebo: Blinded Period | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg | SSD: Cohort 1: Group 1 | SSD: Cohort 1: Group 2 | SSD: Cohort 1: Group 2b | SSD: Cohort 2: Group 3 | SSD: Cohort 2: Group 4 | SSD: Cohort 3: Group 5 | SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg | SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 3998 | 4002 | 491 | 493 | 55 | 50 | 16 | 8 | 9 | 237 | 224 | 31 | 25 | 24 | 26 | 389 | 124 | 250 | 16 | 19 | 15 | 17 | 14 | 16 | 268 | 254 | 261 | 262 | 277 | 272 | 21 | 19 | 21 | 20 | 20 | 21 | 12265 |
| Black or African American | 470 | 457 | 159 | 155 | 11 | 9 | 176 | 172 | 178 | 21 | 34 | 155 | 2 | 3 | 1 | 34 | 10 | 32 | 1 | 0 | 2 | 2 | 2 | 1 | 19 | 22 | 23 | 20 | 13 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 2203 |
| American Indian or Alaska Native | 86 | 92 | 4 | 6 | 0 | 0 | 1 | 0 | 2 | 1 | 4 | 1 | 0 | 0 | 0 | 2 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 206 |
| Asian | 288 | 269 | 61 | 58 | 7 | 5 | 4 | 2 | 1 | 42 | 45 | 1 | 2 | 3 | 3 | 42 | 20 | 25 | 3 | 1 | 2 | 1 | 4 | 3 | 13 | 20 | 16 | 20 | 16 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 994 |
| Native Hawaiian or other Pacific Islander | 7 | 11 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 34 |
| Multiracial | 209 | 197 | 24 | 12 | 1 | 0 | 10 | 11 | 6 | 10 | 12 | 22 | 1 | 0 | 0 | 12 | 2 | 8 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 5 | 6 | 3 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 559 |
| Not reported | 22 | 13 | 13 | 7 | 1 | 0 | 9 | 4 | 8 | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 86 |
| Race/Ethnicity, Customized(Participants) | SSA: BNT162b2 30 mcg: Blinded and Open Label Period | SSA: Placebo: Blinded Period | SSB: BNT162b2 30 mcg Then Placebo | SSB: Placebo Then BNT162b2 30 mcg | SSC: BNT162b2 10 mcg | SSC: BNT162b2 30 mcg | SSD: Cohort 1: Group 1 | SSD: Cohort 1: Group 2 | SSD: Cohort 1: Group 2b | SSD: Cohort 2: Group 3 | SSD: Cohort 2: Group 4 | SSD: Cohort 3: Group 5 | SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg | SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg | SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg | SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg | SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg | SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg | SSF: BNT162b2 30 mcg | SSF: BNT162b2 60 mcg | SSF: BNT162b2 OMI 30 mcg | SSF: BNT162b2 OMI 60 mcg | SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg | SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic/Latino | 759 | 750 | 152 | 150 | 15 | 11 | 6 | 0 | 4 | 48 | 46 | 7 | 3 | 4 | 3 | 66 | 17 | 39 | 1 | 1 | 4 | 3 | 2 | 4 | 57 | 38 | 44 | 46 | 45 | 44 | 0 | 0 | 0 | 0 | 0 | 0 | 2369 |
| Non-Hispanic/non-Latino | 4309 | 4283 | 595 | 577 | 59 | 53 | 209 | 196 | 200 | 266 | 277 | 202 | 27 | 26 | 27 | 413 | 142 | 282 | 19 | 19 | 16 | 17 | 18 | 16 | 248 | 264 | 263 | 261 | 263 | 269 | 21 | 19 | 21 | 20 | 19 | 21 | 13937 |
| Not reported | 12 | 8 | 6 | 5 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 41 |
Showing the first 100 of 154 sites across 5 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2021 to primary completion in May 2023, 22 months.
Results were first posted in Nov 2025, 2 years 5 months after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 22 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BNT162 Vaccine